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 Alpha-tocopherol (αT) is a hydrophobic, antioxidant molecule shown to prevent 
or retard the effects of free radicals associated with diseases.  It is hypothesized that the 
bioavailability of αT can be improved when entrapped in PLGA (Poly lactide-co-
glycolide) and PLGA-Chi (PLGA-Chitosan) nanoparticles and that the mucoadhesive 
properties of chitosan may enhance absorption more than PLGA alone. PLGA and 
PLGA-Chi NPs synthesized with PVA as surfactant were characterized by measuring 
entrapment efficiency, size, PDI, and zeta potential when suspended in DI water. 
Nanoparticle physical stability was evaluated via NP exposure to environmental pH 
ranging from 2.5-9. Chemical stability of entrapped αT was also investigated by exposing 
particles to simulated GI (gastro-intestinal) environments for 48 hours, and release 
kinetics were measured in these conditions for 72 hours. Pharmacokinetic studies were 
conducted by administering PLGA (αT) NPs, PLGA-Chi (αT) NPs, and free αT in a 
flour, water, and corn oil slurry via oral gavage in rats. Blood samples were collected 
over 72 hours. Entrapment efficiency was 95.4 ± 9.85%, for PLGA NPs and 77.95 ± 
1.51% for PLGA-Chi NPs. The size and zeta potential of the two particle systems were 
97.87 ± 2.63 nm and -36.2 ± 1.31 mV for PLGA(αT) NPs,  and 134 ± 2.05 nm and 38.0 ± 
2.90 mV for PLGA-Chi (αT) nanoparticles in DI water. PLGA(αT) NPs showed a change 
in size of only 4 nm in the pH range of 2.5-9, while PLGA-Chi(αT) nanoparticles 
revealed a 46 nm change in size in pH 2.5-9.  Entrapped αT showed no degradation in GI 
conditions over 48 hours. Release kinetics also showed no release of the αT from either 
NP system over 72 hours. Bioavailability of nanodelivered αT was improved as indicated 
compared to the free αT up to 170% and 121% for PLGA and PLGA-Chi NPs, 
respectively. These findings revealed that both delivery systems increased bioavailability 
of αT, but chitosan did not improve uptake of αT, as hypothesized. 








Chapter 1 Introduction 
1.1  Vitamins & Health Benefits 
Vitamins are a group of nutrients that are not synthesized by the human body but 
are necessary for reproduction, repair, growth, and development. Vitamins fall into two 
groups:  fat soluble which includes A, D, E, and K, and water-soluble which includes 
vitamins B and C. These vitamins must be obtained from food, drinks, or supplements 
since they are not synthesized by the body (Murugeshu et al., 2011). In order for vitamins 
to be useful, they must be bioavailable. According to the FDA, bioavailability is defined 
as the rate and extent to which the active drug ingredient or therapeutic moiety is 
absorbed from a drug product and becomes available at the site of drug action (Cohn, 
1997). The bioavailability of vitamins, especially the fat-soluble group, is highly variable 
and somewhat limited due to challenges including insolubility in water and instability due 
to oxidation. Because of these challenges, fat-soluble vitamins must either be dispersed 
into a lipid phase or introduced into a delivery system for enhanced bioavailability. An 
appropriately designed delivery system will encapsulate fat-soluble vitamins such as 
alpha-tocopherol (αT), in a form that protects the bioactive from degradation and 
enhances the bioavailability after ingestion (Yang & McClements, 2013). 
1.1.1  Alpha-tocopherol – Structure, Function and Benefits 
 Alpha-tocopherol (αT) is the most biologically active vitamin E compound, 
accounting for approximately 90% of the vitamin E activity in tissues (Cohn, 1997).  
Vitamin E belongs to a class of lipophilic antioxidant vitamins possessing characteristics 
that prevent cellular damage from reactive oxygen species. αT may indirectly prevent or 
retard disease such as cancer, diabetes, cardiovascular disease, inflammatory responses, 
aging, liver injury, and others due to its antioxidant capacity (Murugeshu et al., 2011).  
 Alpha-tocopherol (structure shown in Figure 1.1) contains a saturated phytyl C16 
side chain and a 6- hydroxyl group which is characteristic of all tocopherols. The side 
chain which is in the 2-position facilitates succesful incorporation of vitamin E in cell 
membranes. Because of the lipophilic nature of alpha-tocopherol, when the side chain is 
in the membrane, the 6-position hydroxyl group is on the perimeter of the membrane, 
optimal for scavaging free radicals and impeding lipid peroxidation. After free radical 
quenching, the unpaired electron on the oxygen atom in the C-6 position can be 
delocalized into the aromatic ring structure which increases stability (Bjorneboe et al., 
1990).  




1.1.2  Alpha-tocopherol—Challenges in Absorption 
 Although health benefits associated with intake of αT are a result of its chemical 
structure, the structure of αT is partly responsible for challenges in absorption following 
oral administration.  Specifically, low mucosal permeability, low solubility of the 
compound, premature elimination prior to absorption, and chemical and enzymatic 
instability in the GI tract are major barriers in absorption of lipophilic vitamins such as 
αT (Murugeshu et al., 2011).  According to Barker et al. (2003), one challenge in proper 
absorption associated with the structure of αT is the accelerated degradation as a result of 
its low oxidative stability when exposed to heat and oxygen (Song et al., 2009). 
According to Murugeshu et al. (2011), the efficiency of absorption of tocopherols was 
reported to be approximately 36% in normal subjects, however the conditions were not 
reported. This absorption efficiency is highly dependent on the chemical form and the 
nature of the matrix in which the αT is suspended or dissolved (Yang & McClements, 
2013).  
1.1.3  Alpha-tocopherol—Metabolism  
 The fate of vitamin E within the body is linked to dietary fat.  Absorption in the 
intestine requires bile salts, pancreatic enzymes, and adequate fat to be present. In general 
for fat-soluble vitamins, formation of micelles containing dietary lipids, emulsified in the 
presence of bile salts, is necessary for absorption (Lodge, 2005). The bioaccessibility of 
lipophilic bioactives such as αT has been reported to increase as the total amount of 
mixed micelles increases. This bioaccessibility also depends on the nature of the mixed 
micelles present after lipid digestion (Yang & McClements, 2013). Because of this route 
of absorption, variable absorption is likely depending on fed/fasted status of individual 
(Barker et al., 2003). Once vitamin E is internalized into the enterocyte, it is packaged 
into chylomicrons, and it enters circulation via the lymphatic system.  Once the 
chylomicrons are in circulation, the chylomicron triglycerides are subjected to hydrolysis 
via lipoprotein lipase. The result of this process is the transfer of lipids, including αT, to 
peripheral tissues (Lodge, 2005). 
1.2  Pharmacokinetics 
 In order to reach optimum efficacy, a bioactive such as αT must have a high 
bioavailability (Yang & McClements, 2013).  The FDA defines bioavailability as the rate 
and extent to which the active drug ingredient or therapeutic moiety is absorbed from a 
drug product and becomes available at the site of drug action (Cohn, 1997). 
Bioavailability is studied quantitatively in a field called pharmacokinetics. 
Pharmacokinetics (PK) is the study of drug disposition in the body with a focus on 
changes in drug plasma concentration (Brenner & Stevens, 2009).  The rates of four 
processes—absorption, distribution, metabolism, and elimination--determine the rise and 
fall of plasma concentrations of any given drug. Absorption refers to the movement of a 
drug into the bloodstream, and the rate of absorption relies on the physical characteristics 
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of the drug and its formulation. Distribution is the process of the drug leaving the blood 
stream and going into organs and tissues, while metabolism refers to the 
biotransformation of a drug primarily in the liver. Elimination of a drug is the process of 
excretion of the parent compound or its metabolites, typically by the kidneys (Brenner & 
Stevens, 2009).  
 Numerous barriers associated with absorption of drugs are unique to oral 
administration. For example, when a drug is administered orally, it must be absorbed 
through a layer of epithelial cells with tight junctions. In addition, drugs must also avoid 
first-pass biotransformation which occurs when orally administered drugs are absorbed 
from the gut and reach the liver through the hepatic portal vein. A fraction of the drug can 
then be metabolized in the liver before reaching systemic circulation, reducing oral 
bioavailability of the parent compound (Brenner & Stevens, 2009).  Quantitative 
pharmacokinetics is used to determine the efficiency of a formulation to by-pass barriers 
in absorption such as first-pass biotransformation and passage through tight junctions of 
the epithelial cells. To determine the oral bioavailability of a particular drug, the area 
under the curve (AUC) of the drug’s plasma concentration-time curve is needed. This 
curve represents the relationship between drug plasma concentrations with respect to time 
following an acute dose of the drug (Figure 1.2).  
 
Figure 1.2. In the plasma concentration-time curve of a drug, the Y axis is the linear scale 
of drug plasma concentration, typically in µg/ml, and the X axis represents time, typically 
in hours. 
From the drug plasma concentration curve, parameters of pharmacokinetics can 
be obtained. The maximum concentration (Cmax), the time needed to reach the maximum 
concentration (Tmax), and the AUC are the most important parameters to determine 
pharmacokinetic properties of a formulation. The AUC represents a measure of the total 
amount of drug absorbed during the time course, and this value is useful for comparing 
the bioavailability of different formulations. Specifically, oral bioavailability of a certain 
drug is determined by dividing the AUCoral  by the AUCIV (intravenous) (Brenner & Stevens, 

























of two different delivery systems of the same drug. Pharmacokinetic properties are 
important to discover before any drug formulation can be made commercially available.  
1.2.1  Alpha-tocopherol Delivery Systems 
 Studies have been conducted with the intent of enhancing the bioavailability of 
αT by circumventing the challenges associated with its oral delivery.  One group saw an 
18% increase in bioavailability when using at αT-loaded Ca-pectinate microcapsules 
when compared to delivery of free αT (Song et al., 2009). This biopolymeric system was 
based on the use of natural polysaccharides as a safe and effective drug delivery matrix 
that would aid in protection of accelerated degradation of αT due to its low oxidative 
stability and poor solubility in water. The same group previously studied Ca-alginate 
microcapsules, but the initial burst release limited the application of this microparticle 
system for delivery of alpha-tocopherol. 
 An alternative, Ca-pectinate gel microcapsules were produced by Ca-induced 
ionotropic gelation of low methoxyl pectin, producing a nontoxic, biocompatible, 
biodegradable, and structurally strong product. Male rats were given a dose of 10 mg 
αT/kg body weight in free form or entrapped in Ca-pectinate microcapsules.  When free 
αT was given, an immediate increase in plasma αT concentration was observed, and the 
Cmax occurred before 5 h following administration (Figure 1.3). In contrast, the Ca-
pectinate microcapsules showed a much slower increase in plasma concentration of αT, 
with a Cmax occurring at 9 h after administration. These findings reinforce the notion that 
micro and nano delivery systems have the potential to increase bioavailability of a 
bioactive as well as change the pharmacokinetic profile (Song et al., 2009). 
 
 
Figure 1.3. The plasma concentration-time curve as determined in rats represents the 
control αT (●) and  αT delivered in Ca-pectinate microparticles (ο) (Song et al., 2009). 
  
Gelucire 44/14 preparations were reported to double the oral bioavailability of αT 
compared to commercially available αT (Barker et al., 2003). The goal of this study was 
to reduce variable absorption of αT depending on fed/fasted status of an individual and 
also to formulate an appropriate formulation suitable for drugs liquid at room temperature 
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(Barker et al., 2003). Gelucire 44/14 was chosen because of its proven improvement of 
bioavailability and increased dissolution rate. The compound is one of a family of lipid-
based excipients (the Gelucires) which comprises a mixture of pegylated fatty acid esters 
and glycerides, and the two numbers of their names correspond to the approximate 
melting point and HLB value, respectively. This particular study involved comparative 
oral bioavailability in human volunteers between a Gelucire 44/14 formulation of 300 IU 
αT and an equivalent commercial capsule based on an oily solution. The Tmax was the 
same for both commercial and Gelucire 44/14 formulations, which occurred at 10 hours 
following administration (Figure 1.4).  
 
Figure 1.4. The comparison of human plasma concentration over time is shown for αT in 
Gelucire 44/14 preparation (top curve) and commercial αT product (bottom curve) 
(Barker et al., 2003). 
 
The author reported a two-fold increase in absorption of the formulated preparation over 
the control, lending confidence to their premise that Gelucire 44/14 formulation enhances 
bioavailability (Barker et al., 2003).  
In 2010, a study successfully enhanced αT bioavailability by 160% via a nano-
emulsion system (Hatanaka et al., 2010). The purpose of the nano-emulsion system was 
to improve intracellular uptake, stability, and solubility of active substances, in particular, 
αT. The researchers compared several liquid formulations of αT which were prepared by 
a mechanochemical method, and the phases were composed of αT and medium chain 
triglyceride (MCT) for the lipid phase and decaglyceryl monooleate, lecithin, glycerol, 
and DI water for the aqueous phase. Rats were given a dose of 30 mg αT/kg body weight 
in the nano-emulsion form or in free form as a control.  Plasma levels of αT varied 
greatly between the nano-emulsion formulation and the control of αT suspended in MCT 














Figure 1.5. The pharmacokinetic profiles in rats of a control αT solution in MCT (ο) and 
a novel nano-emulsion preparation (□) are represented (Hatanaka et al., 2010).  
1.2.2  Nanoparticles as a Delivery System 
 Nanomedicine is defined by the European Science Foundation as nanometer size 
scale complex systems consisting of at least two components, one of which being the 
active ingredient. Most current research involving nanotechnology explores behavior of 
particles 1-200 nm in diameter, but the size of particles used in drug delivery may range 
from 2-1000 nm (Plapied et al., 2011). Nanoparticles used for delivery of therapeutic 
agents must meet certain criteria. For example, the nanoparticles must be stable, non-
toxic, non-immunogenic, biodegradable, and should be applicable to numerous molecules 
such as proteins, vaccines, nucleic acids, or small drugs such as αT (Plapied et al., 2011). 
 Nanoparticles offer a plethora of advantages to the field of oral drug delivery. The 
growing list of advantages of nanomedicine includes the reduce fed/fasted variable 
absorption, improved dose proportionality, potential to minimize drug attrition rates, 
increased rate of absorption, ability to overcome GI window of absorption, delivery of 
insoluble drugs, targeting of drugs, and transcellular delivery of drugs (Grama et al., 
2011). Because of these advantages, nanomedicines have the potential to increase 
efficacy, specificity, tolerability, and most importantly bioavailability of the 
corresponding drugs (Plapied at al., 2011).  
 Recently, synthesis of polymeric nanoparticles as drug delivery vehicles has taken 
the spotlight due to their pharmaceutical advantages (Grama et al., 2011).  Polymeric 
nanoparticles offer the ability to deliver drugs falling under 4 different classes—Class I 
(high permeability high solubility), Class II (high permeability low solubility), Class III 
(low permeability high solubility) and  Class IV (low permeability low solubility), and 
these nanoparticles can protect the therapeutic ingredient from GI degradation, ensuring 
stability of the drug in the GI tract. In addition to providing protection from harsh 
chemicals and enzymes in the GI tract, polymeric nanocarriers have the ability to increase 
oral bioavailability by withstanding first pass metabolism via their lymphatic uptake 
mechanism (Grama et al., 2011). 
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1.2.3  PLGA 
 Polymeric nanoparticles are favored by some over emulsions for drug delivery 
formulations due to their stability and protection of the entrapped bioactive. Poly (lactide-
co-glycolide) (PLGA) (Figure 1.6) is a promising polymer used for nano-entrapment of 
and delivery of drugs.  
 
Figure 1.6. The structure of PLGA is composed of alternating lactic acid and glycolic 
acid monomers (http://commons.wikimedia.org/wiki/File:PLGA.svg). 
 PLGA is a biocompatible synthetic co-polymer that is commercially available, and it 
degrades into its monomers which are lactic acid and glycolic acid, by-products of the 
citric acid cycle. Because PLGA has been thoroughly characterized and has FDA 
approval, it is the most comprehensively researched commercially available polymer 
(Mittal et al., 2007). 
 PLGA NPs have been shown to improve oral bioavailability of insoluble 
compounds in several references. For example, one group studied the effects on oral 
bioavailability of cyclosporine after entrapment in PLGA nanoparticles stabilized with 
DMAB (Italia et al., 2007). In this study, male rats were given a dose of cyclosporine 
entrapped in PLGA nanoparticles or a control called Sandimmune Neoral® via oral 
gavage of 15 mg/kg body weight.  The results of the in vivo bioavailability study on 
PLGA delivery of cyclosporine is shown in Figure 1.7.  
 
Figure 1.7. The plasma concentration-time curve of cyclosporine delivered in PLGA NPs 
or in a commercial formulation illustrates the controlled-release of PLGA NPs in vivo 




 The pharmacokinetic parameters determined from the plasma concentration-time 
curve shown in Figure 1.7 are summarized in Table 1.1. According to these results, the 
cyclosporine-entrapped PLGA NPs enhanced uptake by 19.2%. 
 
Table 1.1. The pharmacokinetic parameters of cyclosporine delivered in rats are 
summarized (Italia et al., 2007). 
Formulation type Cmax (ng/ml) Tmax (h) AUC0–inf (ng h/ml) 
Sandimmune Neoral® 1448.3 ± 182.4 2 33396.0 ± 4512.9 
Cyclosporine NPs 448.5 ± 61.4 24 39806.7 ± 3970.2 
All values reported are mean ± S.D. (n = 3). 
 Similarly, a study by Mittal et al. (2007) was published showing improved 
bioavailability of estradiol entrapped in PLGA NPs. Estradiol was chosen as the drug of 
interest because although it has a good oral absorption, it has very low bioavailability 
(10%) because of first pass metabolism. This study involved estradiol entrapment into 
PLGA NPs of several different molecular weights and varying lactide:glycolide ratios. 
Male rats were orally gavaged with the equivalent dose of 1 mg estradiol/ rat, and pure 
estradiol was administered orally in 0.05% DMSO solution.  It is evident from the profile 
(Figure 1.8) that the plasma concentration profile of estradiol entrapped in PLGA NPs 
showed a sustained release compared to the control.  
 
Figure 1.8. The different molecular weights of PLGA NPs with entrapped estradiol show 
varying pharmacokinetic profiles. The curves determined from the estradiol entrapped in 
NPs are very different from the curve developed from i.v. administration of the control 
(a) and oral administration of the control (b) (Mittal et al., 2007).  
  
 The 213,000 Da molecular weight PLGA nanoparticles showed a release of 
estradiol over 6 days with a Cmax of 28.55 ng/ml and a Tmax of 32 hours. Oral 
administration of the control only showed a 1 day release profile, with a slightly higher 
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Cmax of 37.08 ng/ml at Tmax of 2 hours (Mittal et al., 2007). The author reports that a 
significant increase (p<0.001) in the AUC values of all the nanoparticle formulations in 
comparison to the orally delivered control was found (Mittal et al., 2007). Several other 
groups found increased bioavailability of drugs orally delivered in PLGA NPs: 
doxorubicin (363%) (Grama et al., 2011), amphotericin B (793%) (Grama et al., 2011), 
and curcumin (2583%) (Grama et al., 2011), (2200%) (Tsai, et al., 2011), (1560%) 
(Khalil et al., 2012). 
1.2.4 Chitosan 
 Chitosan is an additional material of interest in nano-entrapment of bioactives for 
increased bioavailability. Chitosan (Figure 1.9) is formed by N-deacetylation of chitin 
(Plapied et al., 2011).  
  
 
Figure 1.9. Chitosan is an N-deacetylated derivative of chitin. 
 
The beneficial traits of chitosan are its biocompatibility, non-toxic effects, and most 
importantly, its mucoadhesive properties, and this mucoadhesion is believed to be a result 
of chitosan’s positive zeta potential. Mucoadhesion is important because it is understood 
that nanocarriers must adhere to the intestinal mucus to cross this mucus layer. The 
negatively charged intestinal mucosa attracts positively charged particles, making the 
addition of positively-charged chitosan to PLGA nanoparticles a very promising 
approach to increase residence time in the GI tract (Plapied et al., 2011). 
It is hypothesized that the bioavailability of αT can be improved when entrapped 
in PLGA and PLGA/Chitosan nanoparticles and that the mucoadhesive properties of 
chitosan may play a role in enhancing absorption even more so than PLGA alone. 
1.3  Objectives 
 The objectives of this thesis were to conduct a review on biodistribution of PLGA 
nanoparticles in rats and mice (Chapter 2) and to study the effects of nanodelivery on 
bioavailability of a model bioactive (Chapter 3). 
1.3.2  Biodistribution  
 Nanotechnology has the potential to change the face of preventative and clinical 
medicine as it is known today, but in order to utilize the vast applications of these types 
of delivery systems, they must be completely understood and characterized in vivo.  
Certain particles and bioactives have the potential to be toxic to certain organs and tissues 
(Mittal et al., 2007) so knowledge of the NP residence time in each respective organ 
provides direction on how to choose proper delivery systems for specific applications. 
Many unanswered questions refer to particle behavior, toxicity, and clearance 
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 The objective of Chapter 2 was to address these unknowns based on what has 
already been published. Specifically, a review was conducted on biodistribution of PLGA 
NPs delivered in mice and rats. The purpose of the review was to identify correlations 
between particle biodistribution and NP properties (size), animal model (mice and rats), 
type of delivery (intravenous vs oral), and detection method (covalently-linked indicator 
or entrapped indicator). Relative biodistribution of PLGA nanoparticles in various organs 
over time was also reported. This review is entitled “The effect of nanoparticle 
properties, detection method, delivery route, and animal model on poly(lactic-co-
glycolic) acid nanoparticles biodistribution in mice and rats” and it was published in 
Drug Metabolism Reviews in December of 2013. 
1.3.3  Bioavailability 
 The goal of the study reported in Chapter 3 of this thesis was to investigate the 
ability of PLGA and PLGA-Chi NPs to improve bioavailability of a model lipophilic 
bioactive, αT. It was hypothesized that NP systems enhanced bioavailability of αT over 
that of the free vitamin and that PLGA-Chi NPs were more proficient in improving the 
αT bioavailability when compared to PLGA NP delivery.  PLGA and PLGA-Chi NPs 
with entrapped αT were synthesized according to an emulsion evaporation method 
followed by dialysis washing and lyophilization for 48 hours. The NPs were 
characterized in vitro in terms of size, polydispersity index (PDI), zeta potential, release 
kinetics, chemical stability, and physical stability. Next, the ability of PLGA and PLGA-
Chi NPs to improve the bioavailability of the entrapped αT was tested in vivo. Both NP 
systems were gavaged to male rats along with a control of free αT, and the plasma 
concentration of αT was measured over time. The chosen matrix was a flour-in-water and 
oil slurry consisting of 30% oil and 70% flour in water. The NPs were suspended in the 
flour-in-water phase for their delivery, and the free αT was suspended in the oil phase. 
The AUC determined from the plasma concentration of αT in the rats showed a 270% 
increase in bioavailability when delivered in PLGA NPs compared to αT delivered in free 
form. The AUC, and thus bioavailability, of the PLGA-Chi delivered αT was not 
statistically different than the AUC of the PLGA NP delivered αT. This study proved that 
PLGA NPs is a viable and promising delivery system for lipophilic bioactives with poor 




Chapter 2 The Effect of Nanoparticles Properties, Detection Method, 
Delivery Route, and Animal Model on Poly (lactic-co-glycolic) Acid 
Nanoparticles Biodistribution in Mice and Rats1 
 
2.1 Introduction  
 Nanoparticulate delivery systems such as poly(lactic-co-glycolic) acid (PLGA) 
nanoparticles (NPs) are increasing in popularity because they promise to overcome 
numerous biological barriers associated with drug administration (Cartiera, et al., 2009). 
Over the past ten years, research on PLGA NPs as drug delivery systems has increased 
exponentially. Specifically, studies involving intravenous (i.v.) or oral delivery of PLGA 
NPs in mice and rats have been continuously published in an attempt to understand 
implications of PLGA NP behavior in vivo on the toxicity of the delivery system and 
effectiveness of the entrapped drugs.  For example, eight review papers published on 
polymeric NPs were identified, with a focus on biodistribution, biotoxicity, and targeting 
(Acharya et al., 2010; Acharya and Sahoo, 2011; Aggarwal, et al., 2009; Danhier et al., 
2012; Fredenberg et al., 2011; Gaumet, et al., 2008; Owens and Peppas, 2006; Phillips, et 
al., 2010) 
While these review papers contain useful and pertinent information relative to NP 
properties and their specific influence on biodistribution, none of them thoroughly 
discusses PLGA NPs and their behavior in vivo. There is a critical need to compile and 
analyze the abundance of research published on biodistribution of PLGA NPs as a 
function of their physico-chemical properties in an effort to map-out translocation of 
PLGA NP to various organs following oral and i.v. administration. Knowledge of NP 
biodistribution is required to both correlate potential biotoxicity of NPs with their 
properties and to improve the effectiveness of the NPs in treatment or prevention of 
certain diseases.  
 It was the goal of this review paper to compile the available data on PLGA NP 
biodistribution and to quantitatively present NP presence in major tissues over time in 
rats and mice exposed, either orally or intravenously to a single dose of NPs. The effect 
of type of animals used, method employed for NP detection, and NP properties on the 
observed biodistribution trends were also discussed. To reach this goal, a literature search 
was conducted on Science Direct and Web of Science using the following key words: 
biodistribution, NPs, PLGA, polymeric NPs, mice, rats.  
This initial search resulted in 3600 publications, which were then limited to ten 
papers which included information on PLGA NP uptake by major organs, including liver, 
brain, heart, spleen, kidney, and lungs. Each publication found on PLGA biodistribution 
was summarized, highlighting the NP system, method of testing, and major 
biodistribution results.  Emphasis was placed on the particle system, including size, zeta 
                                                          
1 This chapter previously appeared as Simon, Lacey, C. M. Sabliov, “The effect of 
nanoparticle properties, detection method, delivery route, and animal model on 
poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats” in Drug 





potential, surfactants used, loaded drugs, and any surface modifications involved in the 
study. The method used to track NPs in vivo was identified and categorized; these 
methods included detection of fluorescence, detection of radioactivity, or detection of the 
loaded drug. After identifying the specific drug parameters, the procedures for drug 
administration (i.v. or oral) and animal model (mouse or rat) were reported. Lastly, the 
percentage dose NP was listed for major organs tested. 
 
2.2 Organ-by-Organ Biodistribution Analysis 
 The data reported in the featured publications was analyzed with respect to organ 
uptake of PLGA NPs. In order to normalize all data, particle uptake was converted to 
percent dose/g determined in each organ. It is noted that in the papers cited in this review, 
different animals, animal strains, animal ages and animal sexes were used, and sometimes 
the strain, sex, age was not specified. It is understood that organ weight in rodents is 
dependent on these listed (or unlisted) specifications. However, due to a lack of 
specifications in some cases or the inability to identify the organ size for the specific 
situation reported, in all cases an average value was used (Table 2.1).  
Table 2.1. The approximate rat and mouse organ weight (Rat Phenome Database; The 
Jackson Laboratory).  
  mass (g) 
Organ rat mouse 
spleen 0.51 0.12 
liver 8.51 1.22 
lung 0.91 0.152 
brain 21 0.42 
heart  0.91 0.132 
kidney 1.81 0.72 
Available data was analyzed separately for each organ and results were reported on 
nanoparticle biodistribution as a function of time, nanoparticle size, type of indicator, and 
animal model, as follows. 
2.2.1 Liver 
The percent dose detected per gram of liver was compared across ten different 
studies reported on oral delivery of PLGA NPs (Tobio, et al., 2000; Yin, et al., 2007) and 
i.v. delivery of PLGA NPs, (Beletsi, Panagi, and Avgoustakis, 2005; Li, et al., 2001; 
Mondal, et al., 2010; Parveen and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; 
Snehalatha, et al., 2008;  Tosi, et al., 2010; Vergoni, et al., 2009) (Figures 2.1a and 2.1b).  
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Figure 2.1. Comparative biodistribution of nanoparticles (NPs) in the liver are shown in 
(a) rats and (b) mice. Data is presented as percent dose per gram of liver with respect to 
time, after a single dose was administered at time zero. Particle characteristics included in 
the legend are: [reference], nanoparticle size (mean diameter), surfactant (PVA=poly 
vinyl alcohol; P188=poloxamer 188, PEG=poly ethylene glycol), NP dose, detection 
probe (RA=radioactivity, FL=fluorescence, drug=entrapped model drug), location of 
detection probe (EN=entrapped, CL= covalently linked), method of NP administration 
(IV=intravenous delivery, O= oral delivery), and animal model (R=rat, M=mouse) 
(Beletsi, Panagi, and Avgoustakis, 2005; Li, et al., 2001; Mondal, et al., 2010; Parveen 
and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008;  Tobio, et al., 
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 The level of NPs in the liver decreased over a 24 hrs period after a single 
administration of NPs at time zero in both rats and mice (Figures 2.1a and 1 b). For 
example, particles of 170 nm delivered intravenously in rats were detected at 11.2% 
dose/g after thirty minutes following administration, and after 1.5 hours, only 1.8% 
dose/g was detected in the liver (Vergoni, et al., 2009), (Figure 2.1a). In comparison, for 
particles of 258 nm, the % dose/g decreased from 38% at 2 hrs after administration to 
25% dose/g at 24 hours (Parveen and Sahoo, 2011) (Figure 2.1b). This study was done in 
mice, and the particles were also administered via i.v. delivery. The drastic decrease over 
time in both animal models could be associated with rapid uptake of i.v. administered 
NPs from the circulatory system and then clearance from the liver after administration. 
When looking at particle content in the liver at 24 hours, all studies done in rats, 
including (Li, et al., 2001; Tobio et al., 2000; Tosi, et al., 2010; Vergoni, et al., 2009; 
Yin, et al., 2007) showed almost no detection of particles 24 hours post administration.  
The highest detected amount reported was 38% of the administered dose per gram 
of liver for particles delivered intravenously in mice, (Mondal, et al., 2010; Parveen and 
Sahoo, 2011; Snehalatha, et al., 2008) (Figure 2.1b). These systems featured particles 
synthesized with polyvinyl alcohol (PVA) (Parveen and Sahoo, 2011) and poloxamer 188 




It was noted that of the systems showing a high initial uptake, all were 
administered in a mouse model, (Mondal, et al., 2010; Parveen and Sahoo, 2011; 
Snehalatha, et al., 2008), and it was also noted that in general, when expressed as % 
dose/g tissue, NP concentration was higher in mice.  That is to be expected, considering 
that for the same dose of administered NP, the % dose reaching the liver was smaller 
when dividing by the weight of the rat liver, 6-7 times bigger, on average, than liver of 
mice. This principle applies to all organs studied in this analysis; kidney, lung, spleen, 
heart, brain. 
 To make this point, liver uptake of two particle systems of similar characteristics 
was compared across two studies, one done in mice and the other one in rats. Li, et al. 
(2001) tested 200 nm NP in rats and Beletsi, Panagi, and Avgoustakis (2005) tested 96 
nm in mice, both applied doses less than 1 mg, and both systems used entrapped 
radioactivity for detection.  The detected amount of particles in the liver from the system 
delivered in rats was only 1.8% of the administered dose/g liver (Figure 2.1a), whereas 
the amount detected in mice was 23% dose/g liver (Figure 2.1b).  If total % dose/liver 
were to be compared across animals for these two studies, assuming 1.2 g for the mouse 
liver and 8.5 g for the rat liver, similar numbers are found 15.3%  dose/g liver in rats (Li, 
et al., 2001) and 15.6%  dose/g liver in mice (Saxena, Sadoqi, and Shao, 2006). 
NP size  
 Particles of comparable sizes showed similar values detected in the liver. For 
example, particles of 140-200 nm delivered via i.v. delivery in rats were detected 
between 3.5-1.0% dose/g for the first five hours following administration (Tosi, et al., 
2010). Similarly, particles of 170 nm intravenously administered in rats showed uptake of 
1.8-3.5% dose/g between 1-1.5 hrs post administration (Vergoni, et al., 2009), (Figure 
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2.1a). These two systems utilized the same surfactant, mode of administration, animal, 
similar dose, and location of indicator; one used an entrapped drug for indication, and the 
other used an entrapped fluorophore. Similarly in mice, two systems of particles each of 
100 nm were detected at 36% dose/g  (Snehalatha, et al., 2008) and 39.8% dose/g  
(Mondal, et al., 2010) four hours after i.v. delivery (Figure 2.1b).  On the other hand, 
particles of 300 nm delivered in mice were only detected at 5% dose/g liver 4 hours after 
i.v. administration (Saxena, Sadoqi, and Shao, 2006) (Figure 2.1b). The differences in the 
detected NP concentrations with respect to NP size reinforced the notion that smaller 
particles are taken up at higher concentrations in the liver and the similarity in the uptake 
of particles of similar sizes builds confidence in the results obtained across various 
studies. 
2.2.2 Kidney 
The percent dose detected per gram of kidney was compared across nine different 
studies for oral delivery (Yin, et al., 2007), and i.v. delivery (Beletsi, Panagi, and 
Avgoustakis, 2005; Li, et al., 2001; Mondal, et al., 2010; Parveen and Sahoo, 2011; 
Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008;  Tosi, et al., 2010; Vergoni, et 
al., 2009) of PLGA NPs in rats (Figure 2.2a) and mice (Figure 2.2b). Uptake of particles 
for all systems was detected at levels as high as 25% dose/g for rats (Tosi, et al., 2010) 
(Figure 2.2a) and 16.8% dose/g in mice (Parveen and Sahoo, 2011) (Figure 2.2b), 
following administration of a single dose of NPs. All systems but one--(Tosi, et al., 
2010)--were detected at levels below 4% of the injected dose/g of tissue in rats over a 24 
hour period (Figure 2.2a). In mice, all studies reported less than 8% dose/g kidney, with 
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Figure 2.2. Comparative biodistribution of nanoparticles (NPs) in the kidney are shown in 
(a) rats and (b) mice. Data is presented as percent dose per gram of kidney with respect to 
time, after a single dose administered at time zero. Particle characteristics included in the 
legend are: [reference], nanoparticle size (mean diameter), surfactant (PVA=poly vinyl 
alcohol; P188=poloxamer 188, PEG=poly ethylene glycol), NP dose, detection probe 
(RA=radioactivity, FL=fluorescence, drug=entrapped model drug), location of detection 
probe (EN=entrapped, CL= covalently linked), method of NP administration 
(iv=intravenous delivery, o= oral delivery), and animal model (R=rat, M=mouse) 
(Beletsi, Panagi, and Avgoustakis, 2005; Li, et al., 2001; Mondal, et al., 2010; Parveen 
and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008;  Tosi, et al., 
2010; Vergoni, et al., 2009; Yin, et al., 2007). 
Time profile 
A gradual decrease in kidney particle content was seen over time, but four of the 
nine studies showed a significant presence in the kidney even 24 hours after 
administration (Parveen and Sahoo, 2011; Snehalatha, et al., 2008; Tosi, et al., 2010; Yin, 
et al., 2007).  For example, 25% of the dose/g tissue was detected 3 hours following 
administration (Tosi, et al., 2010), and 24 hours after administration, 1.5% of the dose/g 
of tissue still remained (Tosi, et al., 2010) when NPs measuring 140-200 nm were 
delivered intravenously to rats (Figure 2.2a). Similarly, particles with a mean diameter of 
105 nm administered via i.v. delivery to mice were present in the kidney at 6.5% dose/g 
kidney one hour after administration (Snehathala, et al., 2008) and  2% dose/g 24 hours 
post administration (Snehathala, et al., 2008) (Figure 2.2b). 
NP size  
 The data revealed that particle uptake by the kidney was a function of NP size. 
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with mean diameters between 140 and 200 nm used in i.v. delivery in rats showed an 
uptake between 3.5% dose/g and 1.5% dose/g between 1.5-24 hours post administration 
(Tosi, et al., 2010; Vergoni, et al., 2009) (Figure 2.2a).  These particles showed a higher 
uptake in the kidney than did larger particles with a mean diameter of 200 nm also 
delivered intravenously in rats (0.65% dose/g kidney at 3 hours past administration) (Li, 
et al., 2001).  Following the same pattern, particles of 96 nm intravenously administered 
in mice were detected at 8% dose/g after 3 hours post administration (Beletsi, Panagi, and 
Avgoustakis, 2005), and particles of 15-100 nm were detected at 6.8% dose/g 4 hours 
after administration (Mondal, et al., 2010) (Figure 2.2b). On the other hand, particles of 
300 nm intravenously delivered in mice showed only 3% dose/g kidney four hours post 
administration (Saxena, Sadoqi, and Shao, 2006). Size is perhaps the largest common 
denominator differentiating uptake patterns between these various particles, but it is 
important to note that the doses, indicators, and surfactants used were not uniform across 
studies, and these parameters may also have contributed to observed uptake patterns.  
2.2.3 Spleen 
 Ten papers were used to compare PLGA NP uptake in the spleen when 
administered in rats (Li, et al., 2001; Tobio, et al., 2000; Tosi, et al., 2010; Vergoni, et al., 
2009; Yin, et al., 2007), ( (Figure 2.3a) and mice (Beletsi, Panagi, and Avgoustakis, 
2005; Mondal, et al., 2010; Parveen and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; 
Snehalatha, et al., 2008) (Figure 2.3b), and all systems but two (Tobio et al., 2000; Yin, et 
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Figure 2.3. Comparative biodistribution of nanoparticles (NPs) in the spleen are shown in  
(a) rats and (b) mice. Data is presented as percent dose per gram of spleen with respect to 
time, after a single dose administered at time zero. Particle characteristics included in the 
legend are: [reference], nanoparticle size (mean diameter), surfactant (PVA=poly vinyl 
alcohol; P188=poloxamer 188, PEG=poly ethylene glycol), NP dose, detection probe 
(RA=radioactivity, FL=fluorescence, drug=entrapped model drug), location of detection 
probe (EN=entrapped, CL= covalently linked), method of NP administration 
(iv=intravenous delivery, o= oral delivery), and animal model (R=rat, M=mouse) 
(Beletsi, Panagi, and Avgoustakis, 2005; Li, et al., 2001; Mondal, et al., 2010; Parveen 
and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008;  Tobio, et al., 
2000; Tosi, et al., 2010; Vergoni, et al., 2009; Yin, et al., 2007). 
Time profile  
 Of the ten NP treatments used, five showed detectable amounts in the spleen 24 
hours post administration ranging from 0.15-0.4% dose/g in rats (Tobio, et al., 2000; Yin, 
et al., 2007) (Figure 2.3a) and 2.2-13.6% dose/g in mice (Parveen and Sahoo, 2011; 
Snehalatha, et al., 2008)  (Figure 2.3b).  For the first three hours following administration 
in rats, particle uptake in the spleen increased over time. For example, particles of 170 
nm delivered intravenously in rats were detected at 1.2% dose/g at both 0.5 and 1 hour 
post administration; 1.5 hours later, a higher 2.9% dose/g spleen was present (Vergoni, et 
al., 2009). By the same measure, particles of 140-200 nm delivered intravenously in rats 
were detected at 1.7% dose/g one hour following administration, and this concentration 
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2.3a). It was evident that particles were able to maintain consistent levels in the spleen 
over the first four hours following administration in mice as well (Figure 2.3b). For 
example, particles of 300 nm delivered intravenously in mice showed levels of 9% dose/g 
at 30 minutes post-delivery, and 4 hours later, 8.2% dose/g spleen was still present 
(Saxena, Sadoqi, and Shao, 2006) (Figure 2.3b). Following the same pattern, particles of 
105 nm intravenously administered in mice showed 2.4% dose/g one hour after 
administration and 2.6% dose/g 4 hours after administration (Snehalatha, et al., 2008) 
(Figure 2.3b). 
NP size 
  The effect of size on particle uptake in the spleen was shown in rats at three hours 
post administration. Particles of 200 nm delivered via i.v. administration in rats were 
detected at only 0.9-1.46% dose/g spleen three hours after administration (Li, et al., 
2001). On the other hand, smaller particles of 140-200 nm were detected at 2.8% dose/g 
spleen at three hours post administration (Tosi, et al., 2010) (Figure 2.3a). In mice, 
particles of 96 nm were detected at a very high concentration of 50% dose/g of spleen 
(Beletsi, Panagi, and Avgoustakis, 2005) (Figure 2.3b). These particles were delivered 
intravenously and detected on the basis of entrapped radioactivity (Beletsi, Panagi, and 
Avgoustakis, 2005). Similarly, particles of 258 nm showed an uptake of 30% dose/g after 
i.v. administration of particles to mice (Parveen and Sahoo, 2011) (Figure 2.3b). Bigger 
particles measuring 300 nm were found at lower levels of 8-9% dose/g 1-4 hours post i.v. 
administration (Saxena, et. al., 2006) (Figure 2.3b).  It was apparent that the smaller the 
size, the higher the uptake (50% for 96 nm NP, 30% for 258 nm NPs, and 9% for 300 nm 
NPs).  
Type of indicator 
  Four particle systems delivered by i.v. administration in rats with entrapped 
indicators and similar sizes showed very consistent patterns of particle uptake. For 
example, particles of 170 nm with an entrapped drug reached 2.9% dose/g of spleen 
(Vergoni, et al., 2009), and particles of 140-200 nm with entrapped fluorescence reached 
2.8% dose/g of spleen (Tosi, et al., 2010) (Figure 2.3a). Particles of 200 nm with 
entrapped radioactivity reached detection levels of 1.4% dose/g (Li, et al., 2001) (Figure 
2.3a). Only one system used a covalently linked indicator for detection, and these 
particles were only reported at 24 hours (Yin, et al., 2007), showing a minimal uptake, 
near 0.4% dose/g , so no insights can be gained on the effect of type of probe on detection 
(Figure 2.3a). 
 The particle systems in mice showed very similar uptake patterns as seen in rats, 
except for their higher values. Of the particles delivered intravenously to mice, the three 
systems with the largest uptake were systems using entrapped indicators for detection. 
The highest uptake was reported at 50% dose/g for particles of 96 nm delivered i.v. 
(Beletsi, Panagi, and Avgoustakis, 2005) (Figure 2.3b). In contrast, two systems of 
particles intravenously delivered in mice showed a lower uptake when detected based on 
covalently linked radioactivity as indicators. Particles of 105 nm were detected at only 
3.5% dose/g (Snehalatha, et al., 2008) after administration (Figure 2.3b). Similarly, 
particles of 15-100 nm only reached 5% dose/g on average (Mondal, et al., 2010) after 
administration in mice (Figure 2.3b). The difference in uptake can be attributed to the 
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possible release of the radioactive probe when physically entrapped, leading to artificially 
higher uptake reported under these circumstances.  
Method of delivery  
 Direct comparison of biodistribution of particles delivered by i.v. or oral delivery 
can be challenging. For example, two systems delivered orally showed little to no uptake 
in the spleen at 6 and 24 hours post administration in rats (Tobio et al., 2000; Yin, et al., 
2007), whereas i.v. delivered particles were present at 2.9% dose/g spleen (Figure 2.3a). 
Perhaps orally administered particles did not make it to the tissue due to their inability to 
cross barriers or alternatively, the time-frame was too short for these orally delivered 
systems to reach the sampled tissue. If the sampling time had exceeded 24 hours, a larger 
presence of the particles would possibly become evident.  
2.2.4 Lung  
A single dose of NPs was given to mice and rats at time zero, and the particle 
concentration in the lungs was determined for each study for 24 hours following 
administration. Of these NP systems, two were administered orally (Tobio et al., 2000; 
Yin, et al., 2007), and eight were administered intravenously (Beletsi, Panagi, and 
Avgoustakis, 2005; Li, et al., 2001; Mondal, et al., 2010; Parveen and Sahoo, 2011; 
Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008; Tosi, et al., 2010; Vergoni, et 
al., 2009).  Concentrations of particles ranged from 0-29% dose/g in rats (Figure 2.4a) 
and 0.7-21.3% dose/g lung in mice (Figure 2.4b) over the 24 hours following the dose 
administration; at 24 hours, five of the ten NP systems confirmed undetectable levels of 
NPs in the lung (Figures 2.4a and 2.4b). Only NPs of 258 nm i.v. administered to mice 
showed a significant presence of particles at 24 hours, at 20% dose/g of tissue (Parveen 
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Figure 2.4. Comparative biodistribution of nanoparticles (NPs) in the lung are shown in 
(a) rats and (b) mice. Data is presented as percent dose per gram of lung with respect to 
time, after a single dose administered at time zero. Particle characteristics included in the 
legend are: [reference], nanoparticle size (mean diameter), surfactant (PVA=poly vinyl 
alcohol; P188=poloxamer 188, PEG=poly ethylene glycol), NP dose, detection probe 
(RA=radioactivity, FL=fluorescence, drug=entrapped model drug), location of detection 
probe (EN=entrapped, CL= covalently linked), method of NP administration 
(iv=intravenous delivery, o= oral delivery), and animal model (R=rat, M=mouse) 
(Beletsi, Panagi, and Avgoustakis, 2005; Li, et al., 2001; Mondal, et al., 2010; Parveen 
and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008;  Tobio, et al., 
2000; Tosi, et al., 2010; Vergoni, et al., 2009; Yin, et al., 2007). 
Time profile  
Two NP systems, both of approximately 170 nm, showed an immediate high 
uptake by the lungs after i.v. administration in rats. In one system, particles were detected 
at 29% dose/g 30 minutes after administration (Vergoni, et al., 2009).  An hour later, 
these particles were detected at 10.6% dose/g (Vergoni, et al., 2009) (Figure 2.4a). 
Similarly, after one hour, the other particle system of approximately 170 nm showed an 
uptake of 9% dose/g in the lung (Tosi, et al., 2010)  and after five hours, these particles 
were detected at 1% dose/g (Tosi, et al., 2010) (2.4a). Presence of both NP systems was 
reported one hour after administration, and at this time point, the detected amounts only 
differed by 1.4% dose/g (Figure 2.4a). Of the particles delivered to mice with more than 
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of 300 nm delivered intravenously in mice were detected at 5.3% dose/g lung 0.5 hours 
following administration (Saxena, Sadoqi, and Shao, 2006). One half hour later, 4.9% 
dose/g was present, followed by 4.8% dose/g two hours post administration (Saxena, 
Sadoqi, and Shao, 2006) (Figure 2.4b).  
Animal model  
 When similar systems detected with the same method were compared, rats 
showed smaller values of uptake compared to mice. Specifically, particles of 96 nm 
delivered intravenously in mice showed a presence of 13% dose/g lung 3 hours post 
administration (Beletsi, Panagi, and Avgoustakis, 2005), and this value was determined 
using entrapped radioactivity (Figure 2.4b). Particles delivered via i.v. administration in 
rats, on the other hand, showed only 0.9% radioactivity after three hours, and these 
particles were also detected using entrapped radioactivity (Li, et al., 2001) (2.4a). 
Type of indicator 
 For NPs delivered in both mice and rats, the systems showing the highest 
detection were those with entrapped drugs or fluorophores for indication. For example, 
particles of 170 nm with entrapped drug were detected at 30% dose/g thirty minutes after 
i.v. delivery (Vergoni, et al., 2009). Whereas, another system of 140-200 nm particles 
with an entrapped fluorophore was detected at 9% dose/g one hour after i.v. delivery in 
rats (Tosi, et al., 2010) (Figure 2.4a).  These trends were similar in mice; 258 nm 
particles with an entrapped drug i.v. delivered in mice showed an uptake of 21% dose/g 
thirty minutes after delivery (Parveen and Sahoo, 2011) (2.4b). In comparison, 96 nm 
particles with entrapped radioactivity were detected at 13% dose/g 3 hours after i.v. 
administration in mice (Beletsi, Panagi, and Avgoustakis, 2005) (2.4b). The only NPs 
that showed concentrations detected in the lungs greater than 8% dose/g were NPs with 
entrapped probes (Figure 2.4a and 2.4b). 
2.2.5 Heart 
 After a single dose of NPs delivered to mice and rats, concentrations of particles 
in the heart were measured over the 24 hours following administration. Both mice and 
rats were given NPs, and both i.v. delivery (Mondal, et al., 2010; Parveen and Sahoo, 
2011; Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008; Vergoni, et al., 2009), 
and oral delivery (Yin, et al., 2007) were used for particle administration. Only two 
systems were delivered to rats (Figure 2.2.5a), and the remaining four were delivered to 
mice (Figure 2.5b). Five of the six NP systems were found in the heart at levels below 
6% dose/g heart; a high amount (30% dose/g tissue) was detected for only one set of 
particles (Parveen and Sahoo, 2011) (Figure 2.5b). The particles detected at 30% dose/g 
were 258 nm in diameter, detected using the entrapped drug, and delivered intravenously 
to mice. It is important to note that this study reported in general higher uptake than the 





Figure 2.5. Comparative biodistribution of nanoparticles (NPs) in the heart are shown in 
(a) rats and (b) mice. Data is presented as percent dose per gram of heart with respect to 
time, after a single dose administered at time zero. Particle characteristics included in the 
legend are: [reference], nanoparticle size (mean diameter), surfactant (PVA=poly vinyl 
alcohol; P188=poloxamer 188, PEG=poly ethylene glycol), NP dose, detection probe 
(RA=radioactivity, FL=fluorescence, drug=entrapped model drug), location of detection 
probe (EN=entrapped, CL= covalently linked), method of NP administration 
(iv=intravenous delivery, o= oral delivery), and animal model (R=rat, M=mouse) 
(Mondal, et al., 2010; Parveen and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; 
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 Of the data reported in the cited studies, the particle concentration in the heart of 
mice and rats approached 0% dose/g throughout the 24 hours following administration. 
Particles delivered to rats were detected at a maximum of 0.3% dose/g for particles of 
170 nm (Vergoni, et al., 2009) and 0.2% dose/g for particles of 145 nm (Yin, et al., 2007) 
(Figure 2.2.5a).  In mice, particles of 258 nm were delivered intravenously, and 30% 
dose/g was reported in the first hour. Twenty four hours later, this value decreased to 
13% dose/g heart (Parveen and Sahoo, 2011) (2.5b). Four of the six particle systems 
reported showed little to no detection in the heart at 24 hours (Mondal, et al., 2010; 
Snehalatha, et al., 2008; Vergoni, et al., 2009; Yin, et al., 2007) (Figure 2.2.5a and 2.5b). 
It is plausible that the particles of 300 nm approached 0% dose/g 24 hours following 
administration in mice, but data is not reported beyond four hours post administration of 
these particles (Saxena, Sadoqi, and Shao, 2006) (Figure 2.5b).  
Animal model 
 Because of the difference in organ size between mice and rats, it is expected that 
rats have a lower % dose/g detected in any organ.  The data retrieved on heart uptake is 
consistent with this assumption. Particles of 170 nm delivered via i.v. administration in 
rats showed only 0.3% dose/g tissue in the heart for the duration of the particular 
analysis, 0-2 hours post administration (Vergoni, et al., 2009). In mice, particles of 300 
nm were detected at 5.5% dose/g heart both 0.5 and 1 hour post administration (Saxena, 
Sadoqi, and Shao, 2006). 
Type of indicator 
 An uptake of 300 nm particles, administered to mice via i.v. administration, was 
reported at 5.5% dose/g (Saxena, Sadoqi, and Shao, 2006) one hour post administration 
and detected via entrapped fluorescence (Figure 2.5b). This detected dose was much 
higher than that observed in mice intravenously exposed to radioactive NPs measuring 
105 nm (less than 1 % dose/g) (Snehalatha, et al., 2008). The higher values detected for 
the entrapped fluorescent probe could be due to disassociation of the probe from the NPs. 
For example, the studies reporting 30% dose/g (Parveen and Sahoo, 2011) and 5.5% 
dose/g (Saxena, Sadoqi, and Shao, 2006) used an entrapped drug or an entrapped 
fluorescent probe, whereas the study that reported a low % dose/g heart (less than 1%) 
used a covalently linked radiolabel for detection (Mondal, et al., 2010; Snehalatha, et al., 
2008) (2.5b).  
2.2.6 Brain 
 Four NP systems were intravenously administered to rats (Tosi, et al., 2010; 
Vergoni, et al., 2009), and mice (Parveen and Sahoo, 2011; Snehalatha, et al., 2008), and 
their presence was detected in the brain. Three of the four systems showed nearly 
undetectable levels of particles following administration (Snehalatha, et al., 2008; Tosi, et 
al., 2010; Vergoni, et al., 2009).  The highest of this group showed only 0.4% dose/g 
tissue (Tosi, et al., 2010) (Figure 2.6). NPs of 258 nm with an entrapped drug for 
detection showed immediate levels of 6% dose/g of brain following administration, 
consistent with higher values reported by this study across tissue. Even twenty-four hours 
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later, 4.28% dose/g was still present in the brain (Parveen and Sahoo, 2011), shown in 
Figure 2.6. No further insights can be drawn due to the little data reported on brain uptake 
of PLGA NPs.  
Figure 2.6. Comparative biodistribution of nanoparticles (NPs) in the brain are shown in 
rats and mice. Data is presented as percent dose per gram of brain with respect to time, 
after a single dose administered at time zero. Particle characteristics included in the 
legend are: [reference], nanoparticle size (mean diameter), surfactant (PVA=poly vinyl 
alcohol; P188=poloxamer 188, PEG=poly ethylene glycol), NP dose, detection probe 
(RA=radioactivity, FL=fluorescence, drug=entrapped model drug), location of detection 
probe (EN=entrapped, CL= covalently linked), method of NP administration 
(iv=intravenous delivery, o= oral delivery), and animal model (R=rat, M=mouse) 
(Parveen and Sahoo, 2011; Saxena, Sadoqi, and Shao, 2006; Snehalatha, et al., 2008; 
Tosi, et al., 2010; Vergoni, et al., 2009).  
2.3 Discussion 
  The PLGA NPs featured in this review ranged from 15 nm-300 nm and were 
delivered in mice or rats, with covalently linked or entrapped indicators for detection.  
Some particle systems utilized radioactivity while others used fluorescence or an active 
drug for detection.  Although biodistribution of nanoparticles is directly affected by the 
NP system properties, the fate of nanoparticles in vivo is a result of the synergistic effects 
between each of these NP properties. For example, route of administration and particle 
size are both directly related to rate of degradation of the NPs, which then affects 
biodistribution and proper detection of the NPs. On the other hand, increasing sizes can 
allude to slower rates of degradation. By the same token, increasing hydrophilicity of the 
NPs accomplished by addition of various surfactants results in different uptake rates and 
biodistribution profiles. In addition to affecting biodistribution, degradation of particles 
also influences the fate of the associated detection probes. The more deterioration 
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detection probe, whether it is physically entrapped or covalently linked. This 
phenomenon would result in misleading data regarding particle biodistribution. 
 In order to compare particle behavior in vivo, it is important to remember that 
each particle system had a set of characteristics that were not shared with every other 
particle system featured in this review.  Differences in animal model and delivery method 
had the largest influence on particle behavior, but differences in method of detection 
(location of probe), size, surface modification, surfactant, and dose may have also 
affected biodistribution of particles.  
Although inconsistencies exist in the particle characteristics among the studies, 
patterns of biodistribution were identifiable. These patterns are important because they 
give researchers a sense of expectation when designing PLGA NPs for drug delivery in 
mice and rats. When PLGA particles of 140-200 nm were delivered intravenously and 
orally to rats, uptake between 0-4% dose/g liver was detected (Figure 2.1a). On the other 
hand, PLGA particles of 15-300 nm delivered intravenously to mice were detected 
between 5 and 40% dose/g liver over a 24 hour time period following administration, 
depending on their physical characteristics (Figure 2.1b). Similarly, kidney uptake in rats 
showed between 0 and 4% dose/g of particles in the first four hours, but only small 
amounts of particles were detected at 24 hours (Figure 2.2a). In mice, particles of 15-300 
nm were found mostly between 2-8% dose/g kidney. Some particles were still present in 
the kidney up to 2% and 15% dose/g tissue in mice 24 hours after a single dose 
administration (Figure 2.2b). PLGA NPs of 140-200 nm delivered both orally and 
intravenously to rats were detected at values between 1 and 3% dose/g spleen in the first 
two hours following administration (Figure 2.3a). Mice showed a wider range of values 
for spleen uptake of particles; 2.5-9% dose/g tissue was identified in mice after i.v. 
delivery of particles ranging from 15-300 nm (Figure 2.3b). The lungs showed much less 
of a trend in uptake of PLGA NPs than other organs analyzed. In rats, uptake values 
ranged from 9-29% dose/g lungs after delivery in the first two hours (Figure 2.4a). In 
mice, 2.4-21% dose/g tissue was detected in the first two hours (Figure 2.4b). The heart 
and brain showed very little uptake of particles. For both organs in rats and mice, all 
particle systems with two exceptions (Parveen and Sahoo, 2011) (Saxena, Sadoqi, and 
Shao, 2006) were detected between 0-1% dose/g across all time points.  
 Analysis of biodistribution of polymeric NPs over time is critically important. 
Polymeric NPs are designed to be biocompatible and biodegradable; data showing 
clearing of these NP systems from tissue over time would support this concept. The time 
it takes for PLGA NPs to clear the body is different depending on the particle properties. 
From the literature consulted for this review, it was apparent that 24 hours after 
administration (oral or i.v.), the amounts available in tissue is minimal for all PLGA NPs 
studied, of different sizes (15-300 nm), surfactant used (PVA, P188, PEG), NP dose, 
detection probe, location of detection probe, and animal model. 
 For example, in the liver, five of the seven reported particle systems delivered to 
rats were detected at levels under 1.1% dose/g 24 hours following administration (Figure 
2.1a). Similarly, four of the five NP treatments delivered to rats showed less than 1.5% 
dose/g in the kidney at 24 hours (Figure 2.2a). Similar trends were seen in mice. Reported 
values for each mouse organ decreased over time towards 0% dose/g; but few studies 
actually reported a particle concentration at 24 hours in mice, most focusing on the first 
four hours post administration 
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 The data reflected in the reviewed studies reinforced the presumption that size 
affects NP uptake and biodistribution.  According to Parag Aggarwal, et. al, (2009) 
biological responses upon NP administration tend to depend more on surface area than on 
mass.  The smaller the particle, the larger is the surface area to volume ratio. This larger 
surface area creates more room for protein binding of the particles, creating a protein 
“corona”. Specific components of this corona, called opsonins, perhaps enhance uptake 
of the NP by the cells of the reticulo endothelial system (RES). These RES cells are 
highly concentrated in the liver and spleen; and the data has shown higher uptake of 
smaller NPs in both of these organs (Figure 2.1a, Figure 2.1b, Figure 2.3a, Figure 2.3b).  
In addition, it was reported that smaller NPs can penetrate through the fenestrae in the 
endothelial lining of the liver which has a mean diameter of 100 nm (Beletsi, Panagi, and 
Avgoustakis, 2005), and this concept was reinforced by the reviewed data. 
The time profile was different across animal models.  Although mice and rats 
have similar anatomies, their relative organ sizes are not comparable (Table 2.2).  
Therefore, higher levels of NPs might be detected in mice more quickly than in rats, but 
when divided by the organ weight for the same initial dose, the % dose/g tissue is smaller 
in rats than mice. Similarly, the rate at which certain organs show high levels of particles 
varies on the particular organ.  
The time points reported in the literature and included in this review were limited. 
Some publications only showed data from tissue collection once after administration of 
the particles. Others may have reported several different time points after administration, 
but unless each data set used the same time points, comparing data across studies is 
impossible without taking this difference into account. 
Detection of particles in the various organs depends on how long it takes the 
particles to travel in the blood to the particular organ.  When an increase in NP 
concentration is seen over time in organs such as the liver or spleen, it can be attributed to 
a longer blood residence time (Mondal, et al., 2010). This was evident in the spleen, 
which is part of the RES, in both rats and mice. For example, particles of 140-200 nm 
were detected at 1.7% dose/g after 1 hour following administration in rats, but at 3 hours 
post administration, an increased 2.8% dose/g was detected (Tosi, et al., 2010) (Figure 
2.3a). Similar results were seen in the spleen for the first two hours following i.v. 
injection in mice (Parveen and Sahoo, 2011; Snehalatha, et al., 2008) (Figure 2.3b).  This 
increase of uptake in the spleen was perhaps due the reduced NP uptake by the liver 
(Beletsi et al. 2005).   
Each particle in this review utilized an indicator that was either physically 
entrapped in the particle or was covalently linked to the particle. The behavior of the 
radioactive or fluorescent probes in vivo was highly dependent on the location of probe 
association with the NP (covalently linked vs. entrapped). For example, particles of 300 
nm loaded with ICG, used for detection, released 78% of the entrapped ICG in sink 
conditions using phosphate buffered saline at pH 7.4 in just 8 hours (Saxena, Sadoqi, and 
Shao, 2006). Similarly, in particles of 170 nm delivered intravenously in rats, the 
entrapped fluorophore, Rh-123, was used for detection. The association of the Rh-123 
with the NPs was proven under physiological conditions for a time shorter than 2 h. By 
24 hours, 35% of the entrapped Rh-123 was released from the NPs (Vergoni, et al., 
2009). It is possible that at times that exceed 2 h, fluorophores like Rh-123 and ICG may 
leak from the particles and their detection may not be associated with NP presence.   
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It was evident in this review that particles using entrapped probes showed higher 
concentrations in all organs studied (Beletsi, Panagi, and Avgoustakis, 2005; Parveen and 
Sahoo, 2011; Tosi, et al., 2010; Vergoni, et al., 2009). On the other hand, particles using 
covalently linked probes showed much lower concentrations in tissues (Mondal, et al., 
2010; Snehalatha, et al., 2008).  These seemingly lower concentrations may be the most 
accurate of the data sets. According to Yin, et al. (2007), in order to complete an in vivo 
study involving biodistribution, stable binding of fluorescent marker to a polymer as well 
as retainment of fluorescent intensity during assay are required. When 145 nm PLGA 
NPs were synthesized with a covalently linked indicator, only 0.7-0.9% of the marker 
was quenched or released from NPs after 72 hours of artificial gastric and intestinal 
incubation. Because the indicator stayed intact, false results would only result from 
degradation of the polymer, not diffusion of the marker from inside the polymer. 
 The fates of orally ingested particles and intravenously injected particles are 
drastically different.  Biodistribution is one of four processes a drug follows after oral 
delivery, and distribution relies on the first and preceding process, absorption. Absorption 
describes the passage of drug molecules from the location of administration into the 
circulation (Brenner & Stevens, 2009). In oral delivery, NPs must first be absorbed 
through a layer of epithelial cells in the gut that have tight junctions, creating a barrier of 
absorption. In order for an orally delivered NP to reach circulation for further 
distribution, it must cross these biological barriers. NPs administered intravenously by-
pass these biological barriers and enter directly into circulation. It is therefore understood 
that i.v. delivered NPs have 100% bioavailability (Brenner & Stevens, 2009), meaning 
more of the administered dose is available for distribution at a much faster rate. The 
higher percentage of i.v. administered NPs in various tissues when compared to the orally 
delivered NPs was expected. Results reported for orally delivered nanparticles indicated 
that small amounts of particles were absorbed through the gut into the circulatory system.  
 An alternative explanation of the low dose observed over 24 hours in different 
tissues of animals treated orally with PLGA NPs can be the relatively short sampling 
time. One study featuring oral delivery of PLGA NPs but focused only on bioavailability 
of the active drug in the blood indicated that the maximum concentration of 150 nm 
PLGA particles in the blood occurred 12-32 hours post oral administration in rats (Mittal, 
et al., 2007). In contrast, particles of 200 nm delivered intravenously in rats showed a 
maximum concentration 15 minutes after injection (Li, et al., 2001). It is hence possible 
that at longer times, concentrations of orally delivered PLGA NPs may reach higher 
values than those observed in the sampled studies, limited to 24 hours.  
 It is important to note that data is limited on oral delivery of PLGA NPs, and a 
definite gap is present in this area. Only two studies using oral delivery were featured in 
this review, and patterns shown on biodistribution of orally delivered PLGA NPs are 
inconclusive based solely on these two references.  
2.4 Conclusion 
The goal of compiling available data on PLGA NP biodistribution and 
quantitatively presenting NP presence in major tissue over time was achieved in this 
review. The data was converted and combined to provide a uniform, comprehensive 
analysis of published data.  The clarity of the presented data allowed for several trends 
involving PLGA biodistribution in mice and rats to become evident. A range of 
concentrations of NPs was identified for each organ; the liver, lung, kidney, and spleen 
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showed the highest uptake, while the brain showed essentially no uptake. The NP uptake 
was dependent on many characteristics including type of animal, method of delivery, size 
of the NP, and type of indicator used in NP detection. Mice showed higher concentrations 
in tissues than rats, which is expected due to their smaller organs.  Similarly, i.v. delivery 
showed a higher uptake than oral delivery, but little data on oral delivery of PLGA NPs 
exists to reinforce this observation. Smaller sizes were detected in higher concentrations 
in the liver, kidney, and spleen. Finally, physically entrapped indicators were detected in 
higher concentrations, perhaps due to disassociation of the indicator probe from the NP, 
which would cause these values to be misleading. Covalently linked probes showed 
stronger association to the NP in vitro, and they showed smaller concentration values in 
vivo. These smaller values are plausibly more accurate than the larger ones because they 
represent the location of the NP, not the location of a leaked probe.  More data is needed 
to determine trends of oral delivery of PLGA NPs as well as biodistribution profiles of 
particles 24 hours following administration. Despite these gaps in data, this review 
provides researchers a more accurate sense of PLGA NP biodistribution and NP behavior 
in vivo. The scope of the presented information creates a more solid foundation for 
research on improvements in drug delivery and drug efficacy that rely on nanotechnology 





Chapter 3 Bioavailability of Alpha-tocopherol Entrapped in Poly 
(lactide-co-glycolide) (PLGA) and PLGA-Chitosan Nanoparticles 
3.1 Introduction 
Αlpha-tocopherol (αT), a free radical chain-breaking antioxidant, is the most 
bioactive form of vitamin E, and when consumed by humans, has shown to provide 
numerous health benefits (Song, et al., 2009).  This lipophilic antioxidant faces 
challenges common to other orally-delivered lipophilic antioxidants including poor 
solubility in water, oxidative instability when exposed to heat, light, and oxygen, 
chemical and enzymatic instability in the GI tract, and low mucosal permeability (Cohn, 
1997; Murugeshu et al., 2011; Brenner & Stevens, 2010).  In addition, the absorption, 
transport, and distribution of αT is linked to dietary fat (Lodge, 2005).  Because of the 
connection between dietary fat and αT absorption, the bioavailability of αT is highly 
variable. Bioavailability, as defined by the FDA, is the rate and extent to which the active 
drug ingredient or therapeutic moiety is absorbed and becomes available at the site of 
action (Cohn, 1997).  
 Nanoparticles, as alternative delivery systems, have a plethora of advantages over 
other delivery systems including the ability to deliver insoluble drugs, the ability to target 
drugs within the body, and the ability to support transcytosis of a drug across the tight 
intestinal barrier for improved bioavailability. In addition, nanoparticles are able to 
protect the drug from gastro-intestinal degradation, prolong systemic circulation, reduce 
fed/fasted variable absorption, and control the release of the drug (Grama et al., 2011). It 
is therefore expected that with all the aforementioned advantages of nanodelivery 
systems, bioavalability of orally-delivered drugs in nanoform will be improved. Several 
studies indicated that indeed, poly (lactic-co-glycolic) acid (PLGA) NPs have improved 
bioavailability of drugs compared to their free form, such as cyclosporine (119% of free 
form) (Italia et al., 2007), estradiol (1014%) (Mittal et al., 2007), doxorubicin (363%) 
(Grama et al., 2011), amphotericin B (793%) (Grama et al., 2011), and curcumin 
(2583%) (Grama et al., 2011), (2200%) (Tsai, et al., 2011), (1560%) (Khalil et al., 2012).  
 In order to address the variable, and often low, bioavailability of αT, researchers 
have attempted different ways to improve uptake of this bioactive by entrapping it into 
delivery systems.  In general, the area under the curve (AUC) of aT increased for all 
systems studied. When the AUC of the αT delivered to rats in free and nano-emulsion 
systems were compared, the nano-emulsion delivered αT showed a 143% increase in 
bioavailability compared to the control (free) form (Hatanaka et al., 2010).The AUC of 
αT was 18% higher compared to aT delivered in free form when entrapped in a calcium-
pectinate microparticle system and delivered to rats (Song, 2009). A two-fold increase in 
αT bioavailability was achieved in humans when delivered as Gelucire 44/14 product 
(Barker, 2003).   
 Two mechanisms are proposed for improved bioavailability of nanodelivered 
drugs. Either the drug is transported with the nanoparticles as they are transcytosed, or 
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the particles release the load in a controlled manner in the intestine, where it is efficiently 
absorbed. It is suggested that orally administered nanoparticles travel through the GI tract 
where they are absorbed by endocytosis, or by lymphoid uptake, in the “M-cells” in the 
Peyer’s patches (Mittal et al., 2007). Alternatively, the nanoparticles may adhere to the 
M-cells and release only the entrapped drug into the cell. Mucoadhesive nanoparticles are 
believed to improve bioavailability of poorly absorbed drugs because of the strong 
attraction of the particles to the negatively charged mucosa of the intestine responsible 
for a longer residence time in the intestine (plapied et al., 2011). Chitosan can be used to 
confer a positive charge to PLGA NPS when deposited on the surface of the particles via 
electrostatic interaction, to form a mucoadhesive PLGA-Chitosan (PLGA-Chi) NP.  
 It is hypothesized that PLGA and PLGA-Chi nanoparticles will improve the 
bioavailability of nanoparticle-entrapped αT when compared to free αT, and further, it is 
hypothesized that the mucoadhesive properties of PLGA-Chi will increase the 
bioavailability of entrapped αT when compared to αT delivered in PLGA NPs. To test the 
hypotheses, PLGA and PLGA-Chi nanoparticles were orally administered to rats, and the 
pharmacokinetic profiles of the NP-delivered treatment were compared to that of the 
control, or free αT. To better explain the observed pharmacokinetic profile of the NP-
delivered αT, the release kinetics of αT from both NP systems were studied. In addition, 
the physical stability of the NPs and the chemical stability of the entrapped αT were 
examined.  
3.2 Materials 
Poly (D,l-lactide-co-glycolide) (50:50) with a molecular weight of 30,000-60,000 
Da, Polyvinyl alcohol (PVA)  (31,000-50000 Da),  (±)-α-tocopherol (96%), and D-(+)-
Trehalose dehydrate ≥99% were purchased from Sigma Aldrich (MO, USA). Chitosan 
with a molecular weight of 100-300 kDa was purchased from Acros Organics, and ethyl 
acetate was obtained from Macron Chemicals. Nanopure water was obtained with 
Nanopure Diamond (Barnstead international, IA, USA). Acetonitrile and methanol, 
HPLC grade, were obtained from EMD Chemicals (USA). Acetic acid was purchased 
from Fischer Scientific (New Jersey, USA). Gastric media was made up of nanopure 
water, pepsin from porcine gastric mucosa (Sigma Aldrich), hydrochloric acid purchased 
from Fisher Scientific, and sodium chloride also purchased from Fisher Scientific. The 
intestinal media is composed of nanopure water, pancreatin purchased from Sigma 
Aldrich, and sodium hydroxide and potassium hydrogen phosphate both obtained from 
Fisher Scientific. Pasteur pipettes and heparin tubes were both purchased from Fisher 
Scientific. Male F344 rats were purchased from Harlan (Indianapolis, IN, USA). Bio-





3.3.1 Nanoparticle Synthesis 
 PLGA and PLGA-Chi particles with entrapped αT were synthesized using 
emulsion evaporation method modified from Zigoneanu et al. (2008). First, the organic 
phase was composed of 2.5 w/v% PLGA and αT at a 10 w/w% loading relative to PLGA 
mass dissolved in ethyl acetate. The aqueous phase was formed with 2% polyvinyl 
alcohol (PVA) dissolved in ethyl acetate-saturated nanopure water. The organic phase 
was then slowly added to the aqueous phase at an oil to water ratio of 1:5 under 
continuous mixing. After the initial emulsification, the emulsion was subjected to three 
rounds of microfluidization at 30,000 psi to further reduce the size of the droplets. Once 
the emulsion was completely formed, the ethyl acetate was evaporated under vacuum in a 
rotovapor (Buchi R-124, Buchi Analytical Inc., DE, USA). Following complete 
evaporation of ethyl acetate, an aliquot of the sample was used to form PLGA-Chi 
particles.  A 0.01 w/v% chitosan solution was formed using nanopure water spiked with 
acetic acid, creating an acidic environment for proper chitosan solubility. The chitosan 
solution was added to the separated nanoparticle sample at a chitosan concentration of 10 
w/w% relative to PLGA and mixed thoroughly using a magnetic spin bar. The final 
PLGA and PLGA-Chi nanoparticle suspensions were washed by dialysis with a 100 kD 
MWCO membrane suspended in 1.5 L water to remove the PVA, with water changes 
every 8 hours for 72 hours. Finally, particles were lyophilized for 48 hours in the 
presence of trehalose as a cryoprotectant at a trehalose to particle ratio of 1:1. 
3.3.2 Entrapment Efficiency 
Entrapment efficiency of lyophilized nanoparticles was determined by dissolving 
the powder (trehalose and particles) in 95:5 (v/v%) acetonitrile:water at a concentration 
of 0.2 mg mL-1. The solution was sonicated for 1 minute before incubation for two hours 
at ambient temperature. Following incubation, the sample was centrifuged at 30,000 rpm 
for 15 minutes in an Allegra 64R centrifuge (Beckman Coulter, Fullerton, CA, USA), 
then filtered with a 0.2 µm PVDF syringe filter. An Agilent 1200 HPLC (Santa Clara, 
CA, USA) with a binary pump, autosampler, and reverse-phase C18 Xorbax XDB 
column was employed for fluorescent detection of αT at an excitation and emission of 
290 nm and 330 nm, respectively. The mobile phase involved 1mL min-1 gradient flow of 
10% water and 90% methanol, increasing to 100% methanol over 8 minutes. The total 
analysis time was 21 minutes per injection. 25 µl of the filtered sample was injected by 
the autosampler, and the area under the curve produced by the fluorescence detector was 
automatically integrated by Agilent Chemstation software. 
A calibration curve with concentrations ranging from 6 – 0.1 µg/ml αT in 95:5 
acetonitrile:water was produced to determine sample concentration from area under the 
curve. All linear curves used in this study had a correlation coefficient of at least > 0.99, 
and inter and intra-assay variabilities were determined by quantifying n=3 replicates at 
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five different concentrations of αT. Entrapment efficiency was determined by dividing 
the mass of αT per mg of powder by the theoretical mass of αT/mg powder.  
3.3.3 Nanoparticle Morphology, Size, PDI, Zeta Potential 
Particle morphology was identified by transmission electron microscopy (TEM) 
using a JEOL JEM-1400 (JEOL USA Inc., Peabody, MA) system. Lyophilized 
nanoparticles were resuspended in DI water, and one droplet of both PLGA and PLGA-
Chi NPs in suspension was placed on a copper grid of 400 mesh with carbon film. Uranyl 
acetate (2%) was used as a stain, and the sample was dried before analysis. Size, 
polydispersity index (PDI), and zeta potential were measured by dynamic light scattering 
(DLS) using a Malvern Zetasizer Nano ZS (Malvern Instruments, Inc., MA, USA). For 
analysis, freeze-dried NPs were resuspended in deionized water at a concentration of 0.1 
mg ml-1.  One mL of the particle suspension was measured in clear disposable zeta cells 
at 25°C. The refraction index and viscosity were set equal to that specific to DI water. 
The mean values of size, PDI, and zeta potential were determined using a mono-modal 
distribution. 
3.3.4 Nanoparticle Physical Stability 
 The pH stability of the PLGA and PLGA-Chi nanoparticles was determined using 
the Malvern Zetasizer Nano ZS. Particles were suspended in nanopure water that was 
titrated from pH 2.5-9 in increments of 0.5 using dilute HCL and NaOH solutions 
(Murugeshu et al., 2011).  The pH progression was designed to mimic pH change during 
GI transit. Size and zeta potential were determined at each increment of pH 0.5, and one 
measurement per 0.5 pH increment was taken for both PLGA and PLGA/Chi NPs. 
 
3.3.5 Αlpha-tocopherol Chemical Stability 
The chemical stability of αT was determined by exposing both PLGA and PLGA-
Chi NPs with entrapped αT to physiological conditions and measuring the remaining αT 
present in the media. Specifically, the NPs were suspended at 3 mg NPs/ml in simulated 
gastric and intestinal media, and the suspensions were kept at 37 ºC and 100 rpm. The 
simulated gastric media consisted of 3.2 mg/ml pepsin, 0.03M NaCl, and 7ml HCL/l 
media, all dissolved in nanopure water at a pH of 1.2. The intestinal media contained 10 
µg/ml pancreatin, 0.05M kH2PO4, and 0.896 g NaOH/l media, all dissolved in nanopure 
water, at a pH of 6.8. At various time intervals from 0-3 hours (gastric) and 0-72 hours 
(intestinal), a sample of the suspension was centrifuged for 90 minutes at 30,000 rpm, 
and the αT was extracted from both the pellet (NPs) and the supernatant (released αT). 
The amount of αT was determined using the HPLC method described in the entrapment 
efficiency section. The sum of the two quantities revealed the total amount of αT present, 
and this number was compared to the total amount of αT determined by the entrapment 
efficiency at time zero.  
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3.3.6 Nanoparticle Release Kinetics 
In vitro release profiles of αT from PLGA and PLGA-Chi nanoparticles were 
determined under simulated gastric and intestinal environments outlined in section 2.3.5 
(Chemical Stability). Following preparation of the gastric and intestinal environments, 
PLGA and PLGA-Chi particles were suspended in the gastric or intestinal solution at a 
concentration of 3 mg/ml and placed in an incubator at 37°C and 100 rpm. One ml 
samples were collected in triplicate at multiple time points over the course of the 
experiment, 3 h under gastric and 72 h under intestinal conditions. Samples were 
centrifuged at 30,000 rpm for 90 minutes to separate the particles. Following particle 
centrifugation, αT was extracted from the collected particles as previously described for 
entrapment efficiency measurement.  
  
3.3.7 Nanoparticle Delivery Media Preparation 
 In order to confirm that PLGA and PLGA-Chi NPs effectively increased 
bioavailability of entrapped αT when compared to free αT, it was critical to deliver all 
treatments and control in the same media. Since bioavailability of αT is dependent on the 
presence of dietary lipids, a special delivery system was made, keeping the amount of 
lipids constant. The delivery vehicle consisted of a flour-in-water slurry, made up of 300 
mg/ml refined flour, which was combined with corn oil stripped of αT (Bio-Serv, 
Frenchtown, NJ) at a ratio of 30:70. The nanoparticles or free αT was dissolved in this 
slurry prior to delivery.  Each of the treatments included 1.5 mg αT (entrapped in NPs or 
in free form) delivered in the slurry in a 1 ml dose. 
3.3.8 Experimental Animals 
 All experimental protocols involving animals were approved by the Louisiana 
State University Institutional Animal Care and Use Committee (Baton Rouge, LA). Male 
F344 rats (Harlan Laboratories, Indianapolis, IN) weighing 240 ± 6 g were housed two 
per cage and were acclimated for one week with access to food and water ad libitum.  
During the last four days of the acclimation period and duration of the study, the rats 
were fed AIN-93G rodent diet (Bio-Serv, Frenchtown, NJ) which was stripped of all 
tocopherols. The rats were fasted 12 hours prior to treatment with free access to water, 
and n=6 rats were gavaged at time 0 for both treatments and control doses. After gavage, 
the tocopherol-free feed was replaced, and the rats were allowed unlimited access. During 
blood collection, the rats were temporarily anesthetized with isoflurane. Blood was 
collected via the retro-orbital plexus over 72 hours after gavage, and the collection time 
points included 0, 2, 4, 8, 12, 24, 36, 48, and 72 hrs. The collected blood was transferred 
to lithium heparin tubes to prevent clotting, and the plasma was separated from the blood 




3.3.9 Alpha-tocopherol Plasma Concentration Measurement 
The collected plasma was stored at -80 ºC until processing and analysis. In order 
to determine the αT concentration in the plasma, 25 µl of the plasma was thawed and 
spiked with delta-tocopherol (dT) as an internal standard (IS). The final IS concentration 
was 0.1 µg/ml.  Acetonitrile was added to the spiked plasma to precipitate the proteins at 
a 95:5 acetonitrile:plasma ratio. After, the mixture was sonicated for 1 minute in 1.5 ml 
eppendorf tubes and allowed to sit undisturbed for 2.5 hours. The samples were then 
centrifuged at 30,000 rpm for 15, and the supernatant was filtered through a 0.2 µm 
PVDF syringe filter before being subjected to HPLC-MS analysis, as follows. 
          Electrospray analysis was completed using an Agilent 1200 liquid chromatograph 
with autosampler, in sequence with an Agilent 6210 mass spectrometer. The 6210 is an 
ESI – TOF (ElectroSpray Ionization – Time Of Flight) instrument.  Separation was 
accomplished using a Zorbax SB-C18 column (2.1 x 30mm, 3.5-Micron) (Agilent 
Technologies, Santa Clara, CA). The injection volume was 10 µl, with a mobile phase 
consisting of A: water with 0.1% formic acid and B: methanol with 0.1% formic acid at a 
flow rate of 0.2 ml/min. The gradient was as follows: 90% methanol and 10% water at 
time 0, then methanol increased to 100% after 8 minutes. This stayed constant until the 
run is over at 21 minutes after injection.   
  For purposes of data analysis, the following ions were extracted from the total 
chromatogram: 429-431 m/z for αT and 402-403 m/z for dT. Extracting these ions 
resulted in peaks that were integrated using the areas for analysis. A ratio was calculated 
with the area of the αT divided by the area of the dT using MassHunter. 
 The sample data were compared with a calibration curve prepared by spiking 
blank plasma samples with various amounts of a stock solution of αT and a constant 
concentration of 0.1 µg/ml (final) δT internal standard (IS). The following concentrations 
made up the curve: 0.05, 0.1, 0.5, 1.0, and 2.0 µg αT/ml. All linear curves used in this 
study had a correlation coefficient of at least > 0.99. Both inter and intra-assay 
variabilities were determined by quantifying n=3 replicates at five different 
concentrations of αT using the HPLC-MS method described for sample processing. 
 
3.3.10 Pharmacokinetic Analysis 
The pharmacokinetic parameters were calculated using NCSS 9, version 9.0.7 
(Kaysville, UT, USA). The trapezoidal rule was employed to determine the AUC for oral 
administration of both treatments and controls. The area under the concentration-time 
curve (AUC) is a means to quantify the total amount of drug (αT) that reaches systemic 
circulation. The relative bioavailability used in this study (F) is defined as the AUC of the 
drug orally delivered by a specific system divided by the AUC of the drug orally 
delivered in free form. Cmax represents the maximum concentration of the drug detected 




3.3.11 Statistical Analysis 
 The statistical significance of the data was determined using SAS® (SAS Institute 
Inc., Cary, NC, USA). A mixed models analysis of variance with random mixed effects 
procedure was used to estimate the significance of the all data, and difference between 
the means was presumed significant if the p-value was less than or equal to 0.05. 
3.4 Results 
3.4.1 Entrapment efficiency 
 The entrapment efficiency was determined by comparing the amount of αT 
present in the nanoparticles to the theoretical amount of αT used in the synthesis of the 
particles. The amount of αT measured in the PLGA NPs was 25.12 ± 2.6 µg/mg NPs, and 
the amount measured in the PLGA-Chi NPs totaled 19.49 ± 0.38 µg/mg NPs. According 
to the theoretical values, these measurements confirm a 95.4 ± 9.85% entrapment 
efficiency in the PLGA NPs and a 77.95 ± 1.51% entrapment efficiency in the PLGA-Chi 
NPs. 
3.4.2 Nanoparticle morphology, size, polydispersity, and zeta potential 
 The PLGA and PLGA-Chi NPs showed a spherical morphology when measured 
by TEM (Figure 3.1). According to DLS analysis, the PLGA and PLGA-Chi NPs had an 
average diameter of 97.87 ± 2.63 nm and 134.1 ± 2.05 nm and a PDI of 0.156 and 0.298, 
respectively. The zeta potential of the PLGA NPs was -36.2 ±1.31 mV, while the zeta 
potential of the PLGA-Chi NPs was 38.0 ±2.90 mV. 
        
Figure 3.1. PLGA NPs (L) and PLGA-Chi NPs (R) are visibly spherical in shape when 
observed by TEM. 
Although there are numerous limitations in fully simulating physiological 
environments in vitro, useful information can be extracted by exposing nanoparticles to 
conditions that mimic the GI environment. A battery of tests was applied to learn if the 
nanoparticles maintained their nanometer-scale size, if the bioactive was protected by the 
nanodelivery systems during the GI transition, and how much αT was released under 
these conditions.  The information acquired was important in trying to decide whether the 
αT detected in plasma was shuttled across the intestine by the PLGA or PLGA-Chi NPs, 
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or if the particles adhered to the intestinal mucosa and only released αT was absorbed and 
introduced into circulation, free of the particle. 
3.4.3 Nanoparticle Physical Stability  
 The results for pH stability of both particle systems showed very favorable 
results. Throughout the pH titration, the average diameter of the PLGA NPs only changed 
4 nm, from 110 nm-114 nm (Figure 3.2). Even with the neutral zeta potential shown in 
Figure 3.2, the size remained constant. This data builds confidence in the size stability of 
the PLGA NPs in vivo.  
 
Figure 3.2. The change in size (nm) and zeta potential (mV) of PLGA (αT) NPs was 
measured with respect to changing pH showing, a 4 nm increase in size from pH 2.5-9, 
from 110 nm – 114 nm in diameter. 
PLGA-Chi particles showed similar stability under changing pH conditions. 
These particles increased slightly more in size than the PLGA nanoparticles did, but the 
size increase was only from 116 nm to 162 nm (Figure 3.3). The effect of zeta potential 
on size was more apparent for the PLGA-Chi NPs than for the PLGA NPs. As the zeta 
potential approached neutrality with increasing pH, the size of the PLGA-Chi NPs 
increased (Figure 3.3) (Table 3.1). This was expected because stronger zeta potentials 
















































Figure 3.3. The change in size (nm) and zeta potential (mV) of PLGA-Chi (αT) NPs was 
measured with respect to changing pH. In acidic conditions, when the the zeta potential 
was 32 mV, the size was 116 nm. The size and zeta potential reached 162 nm and -0.34 
mV in basic conditions. 
Table 3.1 summarizes the physical properties including size and zeta potential of PLGA 
and PLGA-Chi NPs represented in Figures 3.1-3.3. 
    









size (nm) 97.82 ± 2.63 110.3 114 
zeta (mV) -36.2 ± 1.31 0.345 -1.72 
PLGA-Chi 
NPs 
size (nm) 134.1 ± 2.05 116 129-147 
zeta (mV) 38 ± 2.90 31.8 -0.229 
 
 3.4.4 Αlpha-tocopherol Chemical Stability  
 Knowledge of stability of the αT entrapped in the particles when in simulated GI 
environments is necessary to understand the fate of the nanodelivered αT in vivo, 
especially when determining bioavailability. The results of the chemical stability 
experiment showed no degradation of αT in the particles during the 3 hours they were 
exposed to the gastric environment. From time 0 to 3 hours, 100% of the entrapped αT 
















































Figure 3.4. The total αT present was measured when PLGA and PLGA-Chi NPs were 
exposed to a simulated gastric environment for 3 hours, and 100% of the initial αT was 
detected after 3 hours. 
  
The results of the chemical stability of αT in the simulated intestinal environment 
mirrored that of the stability in the gastric environment. The particles provided protection 
of the αT from degradation during the time frame of analysis (48 h) (Figure 3.5). 
Figure 3.5. The total αT present was measured when PLGA and PLGA-Chi NPs were 
exposed to a simulated intestinal environment for 48 hours, and 100% of the initial αT 
was detected after 48 hours. 
3.4.5 Alpha-tocopherol Release Kinetics  
 The αT found outside of the particles in the gastric environment is shown in 
Figure 3.6.  According to the data, approximately 5% of the entrapped αT was detected 
outside of the NP at time 0. Three hours later, no more αT had been released from either 










































Figure 3.6. PLGA and PLGA-Chi NPs were exposed to a simulated gastric environment 
for 3 hours, and percent of αT released was measured by HPLC over time. Both NP 
systems showed no release of αT between time 0 and 3 hours. 
Immediately after the particles were suspended in the intestinal media, 
approximately 5% of the associated αT was detected outside of the NPs. After 72 hours 
of exposure to the intestinal media, the 95% entrapped αT remained in the PLGA and 
PLGA-Chi particles. The release kinetics showed no differences in behavior between 
PLGA and PLGA-Chi under these conditions (Figure 3.7). 
Figure 3.7. PLGA and PLGA-Chi NPs were exposed to a simulated intestinal 
environment for 72 hours, and percent of αT released was measured by HPLC over time. 
After 72 hours, the amount of αT detected outside the particles had not increased since 
time 0. 
3.4.6 Pharmacokinetic profile 
PLGA and PLGA-Chi NPs were designed to enhance the oral bioavailability of 
lipophilic bioactives. Moreover, αT was used as a model drug not only to determine 
ability of the NPs to improve bioavailability, but also the ability of the mucoadhesive 
properties of PLGA-Chi NPs to improve bioavailability when compared to PLGA NPs 







































NPs, and in free form, the concentration of αT in the plasma was measured and plotted in 
terms of time (Figure 3.8).  
Free αT showed a rapid uptake and clearance after administration. The Cmax was 
2.91 µg/ml and occurred at a Tmax of 8 hours following oral gavage. At 12 hours, the 
plasma concentration of free αT was approaching the baseline. On the other hand, both 
NP-delivered systems showed a distinct uptake pattern compared to the free αT. At two 
hours after administration, an increase in plasma concentration was evident, but four 
hours later, the concentration of αT delivered by both NP systems increased to over 3 
µg/ml (Figure 3.8). These values stayed constant over the following 8 hours, where the 
PLGA NP-delivered αT measured 3.35 µg/ml plasma and the PLGA-Chi NP-delivered 
αT measured 3.9 µg/ml plasma 12 hours following administration (Figure 3.8). Twenty-
four hours after administration, plasma concentration of αT delivered by both NP systems 
was decreasing. This decrease continued until baseline levels of αT were reached by αT 
delivered by both PLGA and PLGA-Chi NPs (Figure 3.8). 
 
 
Figure 3.8. The pharmacokinetic parameters were obtained when the rat plasma 
concentrations (µg/ml) of αT delivered in PLGA, PLGA-Chi, and in free form were 
plotted as a function of time (n=3). The concentrations were detected using positive ion 




































 From the plasma concentration-time curve, AUC was obtained for each of the 
three curves (Table 3.2). The AUC for the control was 36.64 µg/ml/h. The AUC for the 
αT delivered by PLGA NPs and PLGA-Chi NPs were 99.0 µg/ml/h and 80.92 µg/ml/h, 
respectively. According to these values, the bioavailability of the treatment delivered by 
PLGA was 170% higher than the control. Similarly, the bioavailability of the bioactive 
delivered in PLGA-Chi NPs was improved by 121% compared to the free αT. These 
values illustrate that both NP systems significantly improve bioavailability of lipophilic 
bioactives when orally delivered in rats, but PLGA-Chi NPs do not improve the 
bioavailability when compared with PLGA NPs under these conditions. 
Table 3.2. The pharmacokinetic parameters of Tmax, Cmax, and AUC were obtained for 
both treatments and the control from the plasma concentration-time curve (Figure 3.8) 
using NCSS 9 version 9.0.7 (NCSS, LLC. Kaysville, UT, USA). *There was no statistical 







Free αT 8 2.91 36.64 
PLGA NPS 4-12* 3.81 99.00 
PLGA-Chi NPS 12 3.92 80.93 
 
3.5 Discussion 
 Particle behavior and in-vivo fate of nanodelivered bioactives is not a result of 
one, isolated parameter, rather it is heavily influenced by the interdependence of many 
parameters such as nanoparticle characteristics (e.g. size, surfactant, zeta potential),  type 
of bioactive (e.g. hydrophobic or hydrophilic), and media to which exposed (e.g. gastric, 
intestinal, blood).  
 Immediately following freeze-drying, the physical characteristics of PLGA and 
PLGA-Chi NPs showed similarities in size but differences in zeta potential. Specifically, 
they measured 97.87 ± 2.63 nm and 134.1 ± 2.05 nm for PLGA and PLGA Chi NPs, 
respectively. In terms of zeta potential, PLGA NPs were very negatively charged (-36 ± 
1.31 mV) and PLGA-Chi NPs were very positively charged (38 ± 2.9 mV) when 
suspended in DI water at pH approximately 5.5. Although differences in the particles 
were apparent in water, when the particles were exposed to GI conditions, the varying 
characteristics changed in a way that made both PLGA and PLGA-Chi NPs very similar. 
For example, when the particles were exposed to pH changes mimicking GI transit, the 
size in the gastric environment was 110 nm for PLGA NPs and 116 nm for PLGA-Chi 
NPs (Table 3.1). The zeta potential of the PLGA NPs became neutral (0.345 mV), but the 
zeta potential of the PLGA-Chi NPs remained strong (31.8 mV). The major characteristic 
separating the two NP systems when freshly made and suspended in water—zeta 
potential--was no longer a factor under intestinal conditions. The zeta potentials of both 
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particle systems reached neutrality, measuring -1.72 mV (PLGA NPs) and -0.229 mV 
(PLGA-Chi NPs) in conditions with intestinal pH (Table 3.1). Because of the neutral zeta 
potential of the PLGA-Chi NPs, an increase in size from 116 nm to 129-147 nm was 
evident (Table 3.1). Further, we saw no difference in protection of αT when both PLGA 
and PLGA-Chi NPs were exposed to simulated gastric and intestinal conditions over 48 
hours. Both particle systems were synthesized using the same amount of PVA, which in 
addition to the PLGA matrix proved to be protective of NP degradation in simulated GI 
environments. 
 Release of the entrapped bioactive from PLGA NPs has been reported as a 
“diffusion-cum-degradation-mediated” process. This means that during the early stages, 
release occurs via diffusion through the polymer matrix. In the later phases, the release 
occurs by both diffusion through the matrix and degradation of the matrix itself (Panyam 
et al., 2003). Over the time frame of this experiment, it was apparent that release was in 
the early stages of the diffusion phase and no degradation occurred, as supported by 
others as well (Cai et al., 2003; Panyam et al., 2003). Αlpha-tocopherol is a very non-
polar compound, and its tendency to diffuse out from inside the lipophilic matrix of 
PLGA into a polar environment is not likely. In addition, PVA has been shown to provide 
a strong barrier against degradative molecules penetrating the PLGA matrix. (Grama et 
al., 2011; Panyam et al., 2003). 
 The physical and chemical characteristics of PLGA and PLGA-Chi NPs featured 
in this study aid in understanding the behavior of the NP systems in vivo. The analysis of 
the bioavailability data (Figure 3.8) was approached with the in vitro findings in mind. It 
was apparent that αT was protected by the NP systems in the simulated GI environments 
and no αT was released from the particles between time 0 and 3h (gastric) and 0 and 72 h 
(intestinal). From these findings, it must be concluded that the αT was shuttled to the 
intestinal barrier in entrapped form. From this data, it is impossible to determine the 
physical condition of the particles as they cross the intestinal barrier and reach systemic 
circulation. The NPs could either be endocytosed by the enterocytes, transcytosed 
through the enterocytes, transported paracellularly, or taken up by the M cells of the 
Peyers’ Patches found in the gut associated lymphoid tissue (Italia et al., 2011). 
Rergardless of the route to systemic circulation, it cannot be concluded from this data 
whether the αT detected in the plasma was free or still physically entrapped by the NP. 
The goal of this study was to determine if PLGA and PLGA-Chi NPs improved 
the bioavailability of lipophilic antioxidants (αT) by reducing variable absorption and if 
the mucoadhesive properties of chitosan improved this bioavailability even further than 
PLGA NPs.  The PK profile in Figure 3.8 confirmed that nano-delivery improves 
bioavailability of αT by more than 100% (p <0.05). Further, when we compared the AUC 
of αT delivered in PLGA and PLGA-Chi NPs to that of freely delivered αT, the relative 
bioavailability of αT was 270% and 220%, respectively. No statistical difference was 
found between the PLGA and PLGA-Chi delivered αT (p > 0.05).  
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 Similar results on improved bioavailability were seen in other studies using 
PLGA NPs as a delivery system. Estradiol-loaded PLGA NPs orally delivered in rats 
showed a 9-fold improvement in bioavailability and Tmax of 12-32 h depending on the 
molecular weight of the particle, compared to a Tmax of 2 h when estradiol was delivered 
in free form (Mittal et al. 2007). Similarly, curcumin-loaded PLGA NPs delivered in rats 
showed an improved bioavailability of 15.6-fold compared to freely administered 
curcumin. The Tmax of the NP-delivered curcumin was 2 h, while the freely delivered 
curcumin was 0.5h (Khalil et al. 2012). Cyclosporine was no exception when delivered 
by PLGA NPs. When 15 mg/kg body weight was delivered to rats, the NP-delivered drug 
showed a 19% higher absorption than the commercially-available drug Sandimmune 
Neoral®. Perhaps this increase was not as significant as previously reported in the 
literature because Sandimmune Neoral is contains cyclosporine in the form of a 
mircoemulsion, which has shown better uptake capability than free form (Italia et al. 
2007). While the NPs did not show a significant improvement in bioavailability of 
cyclosporine, they did significantly change the PK profile of the drug. Moreover, the Tmax 
of the NP delivered cyclosporine was 24 h, while the commercially available dose was 2 
h after oral administration. This published data combined with the current study on αT 
infers that PLGA NPs not only improved the bioavailability of poorly absorbed drugs, but 
they also significantly changed the pharmacokinetic profile of the drug. 
 The bioavailability of αT delivered in PLGA NPs was 270% of the control αT; 
this improvement was seen in other αT delivery systems. For example, αT-loaded Ca-
pectinate microcapsules increased bioavailability compared to free αT by 118% in rats 
(Song et al. 2009). ΑT bioavailability was improved by 200% in gelucire 44/14 products 
in humans (Barker et al 2003).  By the same token, a nano-emulsion system increased 
bioavailability of αT by 260% in rats (Hatanaka et al. 2010). Although it seems redundant 
to have many delivery systems accomplishing the same goal, we must keep in mind that 
αT serves as a model bioactive to determine the efficacy of PLGA as a nanodelivery 
system. From the results of this study, we see that not only are PLGA and PLGA-Chi 
NPs efficient drug carriers, but they offer an abundance of advantages over other delivery 
systems in addition to improving bioavailability. Unlike other delivery systems, 
polymeric nanoparticles like PLGA are capable of protecting the entrapped drug from the 
GI environment, they can be tailored to desired release properties, and they are geared 
towards the size-dependent uptake suited to the intestinal membrane. PLGA NPs are a 







Chapter 4  Conclusions and Future Work 
4.1 Conclusions 
 Polymeric nanoparticles such as PLGA were proposed to address challenges in 
delivery of poorly absorbed drugs. The first step in determining the effectiveness of 
PLGA NPs as a delivery system was discovering nanoparticle accumulation and 
elimination in vivo. Because of the popularity of PLGA NPs as delivery systems in 
medical research, there was enough data to compile biodistribution trends of PLGA NPs 
in vivo into a comprehensive review paper. The most important trends extracted from the 
data included the following: 1. Minimal amounts of NPs reached the brain and heart, and 
of the NPs that did reach these organs, rapid clearance was evident. 2. Higher 
nanoparticle presence was detected when physically entrapped indicators (dyes, 
fluorophors, entrapped drugs, etc.) were measured rather than covalently linked 
indicators. 3.  Concentration of nanoparticles in various organs was higher in 
intravenously delivered NPs than orally-delivered NPs of similar properties. 4. Published 
data on orally-delivered PLGA NPs was minimal. 
 The lack of data on orally delivered PLGA NPs presented an opportunity to 
investigate the ability of PLGA NPs to improve bioavailability of a model hydrophobic 
bioactive (αT) when delivered orally in rats. In addition, it was an opportunity to improve 
upon PLGA NPs’ ability to shuttle drugs by adding chitosan, a mucoadhesive compound, 
on the surface of the particles. The results indicated that both particle systems were able 
to improve the bioavailability of the αT by over 200%. However, PLGA-Chi NPs did not 
improve bioavailability of the αT delivered over that delivered by PLGA NPs. This was 
likely due to the similar properties of PLGA and PLGA-Chi NPs under simulated 
intestinal environment, where absorption occurs. Through the bioavailability study, the 
effectiveness of PLGA NPs to improve bioavailability of an entrapped bioactive was 
demonstrated. PLGA NPs were proven eligible as a delivery systems that can protect the 
bioactive from degradation by preventing release and maintaining its size stability in GI 
conditions which are advantages of polymeric nanodelivery systems. 
4.2 Future Work  
 In order for PLGA nanodelivery systems to be employed as a suitable drug-
delivery vehicle, more questions should be answered in addition to physical stability of 
the particles and chemical stability of the entrapped bioactive.   
1. Biodistribution is one of the most critical parameters to understand before a NP 
can be used commercially as a drug delivery system. Since it was concluded that 
physically entrapped indicators are not as accurate as a covalently-linked 
indicator, more data on biodistribution with orally-delivered covalently-linked 
PLGA NPs is needed. 
2. Nanoparticle-drug association is still unknown in vivo.To determine particle 
association, a proper method of detection would be needed. Covalently-linked 
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indicators such as TRITC could be used to track particle biodistribution in parallel 
with model drug distribution.  
3. Dose-response of orally-administered PLGA NPs is a missing piece of the puzzle 
that would be of great advantage to future use of PLGA NPs as a drug delivery 
system. Specifically, it is unknown what the saturation point of NPs in the 
intestines would be. 
4. There is an evident separation in understanding between cell studies and in vivo 
studies. When the data from these two studies, using the same NP system, is 
compared, it is typically conflicting. We as researchers need to breach the gap in 
order to determine how the NPs are transported from the intestinal wall into 
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Appendix A Particle Characterization 
Table A.1 The physical properties of size, zeta potential, and PDI were measured by DLS 




(nm) PdI ZP (mV) 
size 
(nm) PdI ZP (mV) 
size 
(nm) PdI ZP (mV) 
PLGA NPs 100.9 0.11  -37.2 96.09 0.17  -36.6 96.63 0.18  -34.7 
PLGA-Chi 
NPs 136.2 0.29  35.9 134 0.30  40.0 132.1 0.29  37.0 
 
 
Table A.2. The calibration curve used for the in-vitro studies was generated using the 
listed concentrations, and areas were produced from fluorescent intensity using an 














































Table A.3. The concentration of αT per mg of powder from freshly made PLGA and 





particles (µg aT/mg NP) 
PLGA 237.5 3.73 24.84 
PLGA 144.5 2.27 22.67 
PLGA 177.4 2.78 27.84 
PLGA-chi 126.1 1.98 19.79 
PLGA-Chi 121.5 1.91 19.06 
PLGA-Chi 125 1.96 19.61 
 
Table A.4. The changes in size and zeta potential of PLGA and PLGA-Chi NPs when 
exposed to pH changes mimicking gastric and intestinal conditions as detected by DLS is 
shown. 
PLGA NPs PLGA-Chi NPs 
pH Diameter (nm) 
ZP 
(mV) pH Diameter (nm) ZP (mV) 
2.7 5.4 0.345 2.61 5.22 31.8 
2.85 5.7 0.435 2.87 5.74 30.1 
3.4 6.8 0.178 3.25 6.5 25.5 
3.85 7.7 5.12 3.81 7.62 28.4 
4.6 9.2 2.14 4.44 8.88 20.6 
5.55 11.1 -0.334 5.26 10.52 10.8 
5.64 11.3 -0.628 5.73 11.46 6.25 
7.86 15.7 -1.47 5.81 11.62 6.71 
8.68 17.4 -1.43 7.95 15.9 -0.229 
8.47 16.9 -1.38 8.53 17.06 0.00392 
8.26 16.5 -1.75 8.05 16.1 0.532 













Table A.5. The chemical stability of αT entrapped in PLGA NPs in the gastric 
environment is shown.  
Time 














0 supernatant 22.5 0.35 7.06 138.58 97.42 
0 supernatant 24.8 0.39 7.78 141.44 99.43 
0 supernatant 25.3 0.40 7.94 147.09 103.40 
0 pellet 419.1 6.58 131.52     
0 Pellet 425.9 6.68 133.66     
0 pellet 443.4 6.96 139.15     
1.5 supernatant 23.8 0.37 7.47 143.76 101.06 
1.5 supernatant 21.2 0.33 6.65 137.74 96.83 
1.5 supernatant 23.6 0.37 7.41 158.29 111.28 
1.5 pellet 434.3 6.81 136.29     
1.5 pellet 417.7 6.55 131.08     
1.5 pellet 480.8 7.54 150.89     
3 supernatant 18.7 0.29 5.87 138.36 97.27 
3 supernatant 23 0.36 7.22 139.71 98.22 
3 supernatant 48.4 0.76 15.19 159.05 111.81 
3 pellet 422.2 6.62 132.50     
3 pellet 404.1 6.34 126.82     



















Table A.6. The chemical stability of αT entrapped in PLGA-Chi NPs in the gastric 
environment is shown. 
Time 














0 supernatant 24.3 0.38 7.64 6.81 4.79 
0 supernatant 22.9 0.36 7.20 6.70 4.71 
0 supernatant 23.6 0.37 7.42 6.58 4.62 
0 pellet 408.9 6.43 128.58     
0 pellet 403.4 6.34 126.86     
0 pellet 394.8 6.21 124.15     
1.5 supernatant 24.3 0.38 7.64     
1.5 supernatant 22.2 0.35 6.98 6.85 4.82 
1.5 supernatant 24.6 0.39 7.74 7.06 4.96 
1.5 pellet   0.00 0.00     
1.5 pellet 413.6 6.50 130.06     
1.5 pellet 424.4 6.67 133.46     
3 supernatant 26.3 0.41 8.27 7.49 5.26 
3 supernatant 26.1 0.41 8.21 7.21 5.07 
3 supernatant 25.2 0.40 7.92 6.95 4.88 
3 pellet 449.8 7.07 141.45     
3 pellet 432.3 6.80 135.94     












Table A.7. The chemical stability of αT entrapped in PLGA NPs in the intestinal 
environment is shown. 
Time 














0 pellet 440.9 6.92 138.36 148.12 104.09 
0 pellet 401 6.29 125.84 134.66 94.63 
0 pellet 434.7 6.82 136.42 145.90 102.53 
0 supernatant 31.1 0.49 9.76     
0 supernatant 28.1 0.44 8.82     
0 supernatant 30.2 0.47 9.48     
24 pellet 451.3 7.08 141.63 147.81 103.87 
24 pellet 447.3 7.02 140.37 147.06 103.34 
24 pellet 408.3 6.41 128.13 133.66 93.93 
24 supernatant 19.7 0.31 6.18     
24 supernatant 21.3 0.33 6.68     
24 supernatant 17.6 0.28 5.52     
48 pellet 445.5 6.99 139.81 150.29 105.62 
48 pellet 402.8 6.32 126.41 132.25 92.93 
48 pellet 430.2 6.75 135.01 141.69 99.57 
48 supernatant 33.4 0.52 10.48     
48 supernatant 18.6 0.29 5.84     












Table A.8. The chemical stability of αT entrapped in PLGA NPs in the intestinal 
environment is shown. 
Time 















0 pellet 357 5.60 112.04 118.12 89.49 
0 pellet 361.7 5.68 113.51 118.12 89.49 
0 pellet 371 5.82 116.43 121.48 92.03 
0 supernatant 19.4 0.30 6.09     
0 supernatant 14.7 0.23 4.61     
0 supernatant 16.1 0.25 5.05     
24 pellet 369.2 5.79 115.86 121.29 91.89 
24 pellet 374.5 5.88 117.53 121.92 92.36 
24 pellet 363.5 5.70 114.08 119.06 90.20 
24 supernatant 17.3 0.27 5.43     
24 supernatant 14 0.22 4.39     
24 supernatant 15.9 0.25 4.99     
48 pellet 380.1 5.96 119.28 125.18 94.84 
48 pellet 372.2 5.84 116.81 121.83 92.29 
48 pellet 345.9 5.43 108.55 115.49 87.49 
48 supernatant 18.8 0.29 5.90     
48 supernatant 16 0.25 5.02     












Table A. 9. PLGA (αT) release kinetics are shown as a function of time in the gastric 
environment. 
Time 










0 supernatant 22.5 0.35 7.06 4.96 
0 supernatant 24.8 0.39 7.78 5.47 
0 supernatant 25.3 0.40 7.94 5.58 
0 pellet 419.1 6.58 131.52   
0 pellet 425.9 6.68 133.66   
0 pellet 443.4 6.96 139.15   
1.5 supernatant 23.8 0.37 7.47 5.25 
1.5 supernatant 21.2 0.33 6.65 4.68 
1.5 supernatant 23.6 0.37 7.41 5.21 
1.5 pellet 434.3 6.81 136.29   
1.5 pellet 417.7 6.55 131.08   
1.5 pellet 480.8 7.54 150.89   
3 supernatant 18.7 0.29 5.87 4.13 
3 supernatant 23 0.36 7.22 5.07 
3 supernatant 48.4 0.76 15.19 10.68 
3 pellet 422.2 6.62 132.50   
3 pellet 404.1 6.34 126.82   













Table A.10. PLGA-Chi (αT) release kinetics are shown as a function of time in the 
gastric environment. 
Time 










0 supernatant 24.3 0.38 7.64 5.354947 
0 supernatant 22.9 0.36 7.20 5.046432 
0 supernatant 23.6 0.37 7.42 5.200689 
0 pellet 408.9 6.43 128.58   
0 pellet 403.4 6.34 126.86   
0 pellet 394.8 6.21 124.15   
1.5 supernatant 24.3 0.38 7.64 5.354947 
1.5 supernatant 22.2 0.35 6.98 4.892174 
1.5 supernatant 24.6 0.39 7.74 5.421058 
1.5 pellet   0.00 0.00   
1.5 pellet 413.6 6.50 130.06   
1.5 pellet 424.4 6.67 133.46   
3 supernatant 26.3 0.41 8.27 5.795683 
3 supernatant 26.1 0.41 8.21 5.75161 
3 supernatant 25.2 0.40 7.92 5.553278 
3 pellet 449.8 7.07 141.45   
3 pellet 432.3 6.80 135.94   













Table A.11. PLGA (αT) release kinetics are shown as a function of time in the intestinal 
environment.  
Time 










0 pellet 440.9 6.92 138.36   
0 pellet 401 6.29 125.84   
0 pellet 434.7 6.82 136.42   
0 supernatant 31.1 0.49 9.76 6.86 
0 supernatant 28.1 0.44 8.82 6.20 
0 supernatant 30.2 0.47 9.48 6.66 
24 pellet 451.3 7.08 141.63   
24 pellet 447.3 7.02 140.37   
24 pellet 408.3 6.41 128.13   
24 supernatant 19.7 0.31 6.18 4.35 
24 supernatant 21.3 0.33 6.68 4.70 
24 supernatant 17.6 0.28 5.52 3.88 
48 pellet 445.5 6.99 139.81   
48 pellet 402.8 6.32 126.41   
48 pellet 430.2 6.75 135.01   
48 supernatant 33.4 0.52 10.48 7.37 
48 supernatant 18.6 0.29 5.84 4.10 
48 supernatant 21.3 0.33 6.68 4.70 
72 pellet 486.5 7.63 152.68   
72 pellet 478.7 7.51 150.23   
72 pellet 467 7.33 146.56   
72 supernatant 20.9 0.33 6.56 4.61 
72 supernatant 22 0.35 6.90 4.85 








Table A. 12. PLGA-Chi (αT) release kinetics are shown as a function of time in the 
intestinal environment. 
Time 











0 Pellet  357 5.60 112.04   
0 Pellet 361.7 5.68 113.51   
0 Pellet 371 5.82 116.43   
0 Supernatant 19.4 0.30 6.09 5.12 
0 Supernatant 14.7 0.23 4.61 3.88 
0 Supernatant 16.1 0.25 5.05 4.25 
24 Pellet 369.2 5.79 115.86   
24 Pellet 374.5 5.88 117.53   
24 Pellet 363.5 5.70 114.08   
24 Supernatant 17.3 0.27 5.43 4.56 
24 Supernatant 14 0.22 4.39 3.69 
24 Supernatant 15.9 0.25 4.99 4.19 
48 Pellet 380.1 5.96 119.28   
48 Pellet 372.2 5.84 116.81   
48 pellet 345.9 5.43 108.55   
48 Supernatant 18.8 0.29 5.90 4.96 
48 supernatant  16 0.25 5.02 4.22 
48 Supernatant 22.1 0.35 6.94 5.83 
72 Pellet 356.1 5.59 111.75   
72 Pellet 351.4 5.51 110.28   
72 pellet 336.4 5.28 105.57   
72 Supernatant 19.8 0.31 6.21 5.22 
72 Supernatant 15.8 0.25 4.96 4.17 





Appendix B Pharmacokinetic Data 




αT area dT area  ratio (αT/dT) 
2 7160541 235100 30.45742663 
2 7184827 233000 30.83616738 
2 7690457 234217 32.83475153 
1 3379365 236573 14.28466055 
1 3417733 222070 15.39034088 
1 3028783 203328 14.89604481 
0.5 1827819 212698 8.593494062 
0.5 1782156 211103 8.442115934 
0.5 1588754 214409 7.409922158 
0.1 666610 182978 3.643115566 
0.1 601293 160117 3.755335161 
0.1 outlier   
0.05 479416 141270 3.393615063 
0.05 417037 119547 3.488477335 
0.05 454088 109100 4.162126489 
 
  






























Table B. 2. The pharmacokinetic data from αT delivered in PLGA NPs is shown. The 
concentrations of αT detected in the plasma is reported as an output of HPLC-MS, using 



















0 p1 319558 118070 2.707 -0.010 -0.199 
0 p2 230484 71753 3.212 0.019 0.380 
0 p3 328541 111791 2.939 0.003 0.067 
0 p4 390066 142167 2.744 -0.008 -0.156 
0 p5 96106 26150 3.675 0.046 0.910 
0 p6 90085 28173 3.198 0.018 0.363 
2 p1 149752 45336 3.303 0.024 0.484 
2 p2 133812 37252 3.592 0.041 0.815 
2 p3 184348 55625 3.314 0.025 0.497 
4 p4 193213 50829 3.801 0.053 1.054 
4 p5 449428 80479 5.584 0.155 3.095 
4 p6 575824 62361 9.234 0.364 7.271 
8 p1 164308 32916 4.992 0.121 2.417 
8 p2 184014 38525 4.776 0.109 2.170 
8 p3 191705 27823 6.890 0.229 4.589 
12 p4 210258 40010 5.255 0.136 2.718 
12 p5 200829 40371 4.975 0.120 2.397 
12 p6 170320 23695 7.188 0.247 4.930 
24 p1 121327 29300 4.141 0.072 1.443 
24 p2 196398 48733 4.030 0.066 1.316 
24 p3 163915 25574 6.409 0.202 4.039 
36 p4 81430 18052 4.511 0.093 1.866 
36 p5 152458 42983 3.547 0.038 0.763 
36 p6 214613 53845 3.986 0.063 1.265 
48 p1 291595 119915 2.432 -0.026 -0.513 
48 p2 229252 68643 3.340 0.026 0.526 
48 p3 188444 67754 2.781 -0.006 -0.113 
72 p4 182553 49372 3.698 0.047 0.936 
72 p5 123379 38587 3.197 0.018 0.363 





Table B.3. The pharmacokinetic data from αT delivered in PLGA-Chi NPs is shown. The 
concentrations of αT detected in the plasma is reported as an output of HPLC-MS, using 


















0 c1 165290 56572 2.922 0.002 0.048 
0 c2 333502 97032 3.437 0.032 0.637 
0 c3 164739 55039 2.993 0.006 0.129 
0 c4 233390 84786 2.753 -0.007 -0.146 
0 c5 146409 47884 3.058 0.010 0.203 
0 c6 175241 57748 3.035 0.009 0.177 
2 c1 104149 31033 3.356 0.027 0.545 
2 c2 168415 39915 4.219 0.077 1.533 
2 c3 140442 37848 3.711 0.048 0.951 
4 c4      
4 c5 306620 72875 4.207 0.076 1.519 
4 c6 481188 66237 7.265 0.251 5.018 
8 c1 230614 41512 5.555 0.153 3.062 
8 c2 227163 36052 6.301 0.196 3.915 
8 c3 239327 40217 5.951 0.176 3.514 
12 c4 307815 52522 5.861 0.171 3.411 
12 c5 195076 29054 6.714 0.219 4.388 
12 c6 203286 32116 6.330 0.197 3.948 
24 c1 100829 22553 4.471 0.091 1.821 
24 c2 216540 38153 5.676 0.160 3.199 
24 c3 101880 25896 3.934 0.060 1.206 
36 c4 188545 61501 3.066 0.011 0.213 
36 c5 136310 46838 2.910 0.002 0.035 
36 c6 112290 37562 2.989 0.006 0.125 
48 c1 195817 69764 2.807 -0.004 -0.084 
48 c2      
48 c3 93379 38658 2.416 -0.027 -0.532 
72 c4 182903 66336 2.757 -0.007 -0.141 
72 c5 136720 51141 2.673 -0.012 -0.236 





Table B.4. The pharmacokinetic data from αT delivered in free form is shown. The 
concentrations of αT detected in the plasma is reported as an output of HPLC-MS, using 



















0 f1 147841 51447 2.874 0.000 -0.007 
0 f2 307979 127188 2.421 -0.026 -0.525 
0 f3 114877 31676 3.627 0.043 0.854 
0 f4 318347 100535 3.167 0.016 0.328 
0 f5 142526 43383 3.285 0.023 0.464 
0 f6 151487 43972 3.445 0.032 0.647 
2 f1 176139 42174 4.176 0.074 1.484 
2 f2 94811 30282 3.131 0.014 0.287 
2 f3 100793 34426 2.928 0.003 0.055 
4 f4 279683 115917 2.413 -0.027 -0.535 
4 f5 226559 60655 3.735 0.049 0.979 
4 f6 298929 57010 5.243 0.135 2.705 
8 f1 256692 49495 5.186 0.132 2.639 
8 f2 171808 33016 5.204 0.133 2.659 
8 f3 223061 37993 5.871 0.171 3.423 
12 f4 104249 27924 3.733 0.049 0.977 
12 f5 123203 32080 3.840 0.055 1.099 
12 f6 144347 40102 3.599 0.041 0.823 
24 f1 149697 45406 3.297 0.024 0.477 
24 f2 160855 40859 3.937 0.060 1.209 
24 f3 144661 40915 3.536 0.038 0.750 
36 f4 175425 58066 3.021 0.008 0.162 
36 f5 129749 43077 3.012 0.008 0.151 
36 f6 109567 30563 3.585 0.040 0.807 
48 f1 225784 78297 2.884 0.000 0.004 
48 f2 130627 47036 2.777 -0.006 -0.118 
48 f3 83821.000 30188.000 2.777 -0.006 -0.118 
72 f4 229277.000 71001.000 3.229 0.020 0.400 
72 f5 135061.000 52258.000 2.585 -0.017 -0.338 
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